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RESUMO  
 
A doença de Crohn, de etiologia desconhecida, caracteriza-se por uma resposta inflamatória crónica 
que envolve todo o trato gastrointestinal, uma elevada heterogeneidade clínica e um forte 
envolvimento de fatores genéticos. Atualmente, ainda não existe nenhuma cura disponível e é sabido 
que os doentes de Crohn, ao longo da sua vida, vão alternando entre períodos de doença ativa e 
períodos de remissão. Trata-se de uma doença que ocorre principalmente entre os 20-30 anos e 
apresenta uma maior incidência em países industrializados, o que parece sugerir a importância de 
fatores ambientais na sua patogénese, onde a dieta tem sido apontada como um fator possível.  
A doença de Crohn encontra-se vulgarmente associada a má nutrição e perda de peso resultantes 
da redução da ingestão de alimentos, hábitos alimentares incorretos, desenvolvimento do processo 
inflamatório característico desta doença e efeitos secundários derivados das múltiplas terapias 
aplicadas no tratamento da doença. Vários estudos têm sido realizados com o intuito de identificar 
quais os alimentos responsáveis pelo agravamento dos sintomas observados na doença de Crohn. 
Os principais macronutrientes prejudiciais a este tipo de doentes são os açúcares e as gorduras, 
principalmente as saturadas, polinsaturadas e trans. Vulgarmente, são também observadas 
deficiências em micronutrientes como o ferro, magnésio, zinco, cálcio e vitaminas A, D, K, B6, ácido 
fólico, cobalamina e ácido ascórbico. Como principais recomendações, os doentes de Crohn devem 
ter uma dieta rica em ácidos gordos, principalmente ómega 3, fruta, vegetais e proteínas, 
nomeadamente carnes magras e ovos. A importância da definição de hábitos alimentares específicos 
a cada doente reside nas premissas que os nutrientes conseguem influenciar direta ou indiretamente 
a expressão de genes e os efeitos da dieta no desenvolvimento da doença dependem do perfil de 
suscetibilidade genética individual. Desta forma, é possível a identificação e caracterização de 
polimorfismos genéticos responsáveis pela alteração do metabolismo dos nutrientes, permitindo deste 
modo a personalização da dieta a cada doente de Crohn com base no seu perfil genético. 
Atualmente, a doença de Crohn define-se como uma doença crónica resultante da interação entre 
fatores clínicos, genéticos e ambientais, apresentando na Europa uma taxa de mortalidade de 
aproximadamente 40%. Em conjunto com a Colite Ulcerosa, constitui o grupo das Doenças 
Inflamatórias Intestinais. A Colite Ulcerosa é também uma doença inflamatória crónica caracterizada 
por um fenótipo específico, predisposição genética, fatores ambientais e resposta imunitária não 
controlada ao microbioma intestinal. 
Com a utilização de estudos de associações genéticas foi possível a identificação de genes de 
suscetibilidade ao desenvolvimento da doença de Crohn. Um dos primeiros e mais importantes genes 
de suscetibilidade associados à doença de Crohn é o gene do núcleo de oligomerização de domínio 2 
(NOD2), já anteriormente descrito como um gene significativamente associado ao risco de 
desenvolvimento da doença de Crohn. Outros genes foram posteriormente identificados e encontram-
se relacionados com o processo inflamatório, nomeadamente citocinas pró-inflamatórias como 
interferão gama (IFNγ), fator de necrose tumoral alfa (TNFα), interleucina 1, 6, 12 e 23 e citocinas 
anti-inflamatórias como o antagonista do recetor da interleucina 1. Foram também identificados 
diferentes genes apoptóticos como o Fas, ligando do Fas e caspase 9, em consequência da 
persistente não resposta à apoptose usualmente observada em diferentes tipos de células nos vários 
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locais de inflamação intestinal, que é característica da doença de Crohn. Recentemente, grande 
atenção tem sido dada à investigação de genes autofágicos, nomeadamente os genes ATG16L1 e 
IRGM, e ao gene de resistência a drogas (MDR1), dada a sua associação à patogénese da doença 
de Crohn. 
Atualmente, a terapia aplicada aos doentes de Crohn envolve o tratamento com aminosalicilatos, 
corticosteroides, imunossupressores e terapia biológica. As recomendações para a terapêutica a 
aplicar aos doentes de Crohn aconselham o início do tratamento com mesalamina e corticosteroides, 
seguindo-se a azatioprina e, finalmente, as terapias biológicas com anticorpos monoclonais anti- 
TNFα em pacientes cuja terapia convencional anteriormente aplicada não tenha sido eficaz. 
O tratamento desta doença é complexo devido à severidade dos parâmetros clínicos e à variedade 
de respostas do doente a cada terapia, e deve por isso contabilizar fatores clínicos como a 
localização da doença, o comportamento da doença e a agressividade da doença, mas também a 
conjugação com fatores genéticos que englobem polimorfismos em genes chave envolvidos na 
resposta inflamatória, na apoptose, na autofagia e no metabolismo e transporte de fármacos.  
O grande desafio existente resulta da dificuldade em prever o desenvolvimento da doença ao longo 
dos anos, o que dificulta a escolha da terapêutica a aplicar e o controlo dos sintomas. 
Com o intuito de responder a esta questão, desenvolvemos um conjunto de estudos aqui 
compilados nesta dissertação que tiveram como objetivo principal identificar fatores clínicos e 
genéticos preditivos da resposta à terapêutica numa população de doentes de Crohn provenientes de 
diferentes hospitais do centro de Portugal. Para tal, procedemos à recolha dos dados clínicos dos 
pacientes, à análise genética através das técnicas de PCR/RFLP e PCR em tempo real de 
polimorfismos relevantes envolvidos no processo inflamatório, apoptose, autofagia e transporte de 
drogas, ao estudo dos seus hábitos alimentares e, por fim, à recolha dos dados de resposta à 
terapêutica aplicada a cada indivíduo. Como objectivos específicos pretendemos: a) estudar as 
associações entre os genes MDR1, IL23R, ATG16L1, Fas, FasL, Casp9 e os parâmetros clínicos 
como idade de diagnóstico, localização da doença, comportamento da doença, agressividade da 
doença, fístulas e manifestações extraintestinais; b) estudar a associação entre os polimorfismos no 
gene MDR1 e a resposta à terapia com aminosalicilatos, corticosteroides e imunossupressores; c) 
estudar a associação entre os polimorfismos nos genes apoptóticos Fas, FasL e Casp9 e a resposta 
à terapêutica biológica; d) estudar a associação entre os polimorfismos no gene IL23R e a resposta à 
terapêutica com corticosteroides, imunossupressores e terapia biológica; e) avaliação global da 
importância da farmacogenética no tratamento da doença de Crohn e, finalmente, a importância da 
nutrigenética no tratamento da doença de Crohn. 
Estes fatores vão permitir a identificação de parâmetros específicos de forma a que o clínico possa 
proceder a uma estratificação dos seus pacientes, aplicando uma terapia mais personalizada de 
acordo com o perfil genético de cada indivíduo. 
Como principais resultados referem-se a identificação de polimorfismos genéticos em citocinas 
como TNFα, LTα, IL1 e IL6 como associados à severidade e desenvolvimento da doença. O 
consumo elevado de açúcares, lípidos e gorduras saturadas, monoinsaturadas e polinsaturadas foi 
identificado como fator de risco para uma elevada atividade da doença. Fatores clínicos preditivos da 
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resposta à terapêutica como a idade, a realização de cirurgia e o envolvimento perianal e fatores 
genéticos preditivos da resposta à terapêutica como polimorfismos genéticos nos genes Casp9 e 
MDR1 foram também identificados. 
Durante a próxima década são esperados desenvolvimentos no conhecimento da terapêutica 
vulgarmente aplicada para o tratamento da doença de Crohn, o aparecimento de novos alvos 
terapêuticos e um maior conhecimento dos fatores genéticos que influenciam a resposta à terapia. 
O futuro do tratamento da doença de Crohn reside no investimento em estudos nas componentes 
de farmacogenética e nutrigenética, como os aqui descritos, uma vez que surgem como uma mais 
valia para a rotina médica diária. Este tipo de estudos vão permitir uma aplicação da terapêutica e 
dieta nutricional direcionadas a cada paciente, de acordo com um conjunto de recomendações 
identificadas que possibilitam uma terapia mais personalizada, com uma maior taxa de sucesso e 
redução de efeitos secundários, permitindo assim um maior controlo da doença na rotina diária dos 
doentes de Crohn.  
 
 
 
 
Termos-chave: Doença de Crohn, Doenças Inflamatórias Intestinais, Farmacogenética, 
Nutrigenética, Medicina personalizada. 
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ABSTRACT 
 
Crohn’s disease, a pathology of unknown origin, is characterized by a chronic inflammatory response 
that involves the entire gastrointestinal tract, a high heterogeneity in phenotype and a strong genetic 
component. It’s a disease with a greater incidence in industrialized countries, what suggests the 
importance of environmental factors in its pathogenesis, where diet patterns have been pointed out as 
possible cause. 
The treatment of this disease is very complex due to the severity of the clinical parameters and the 
variety of response to the existing therapies. This emphasizes the importance of the conjugation with 
genetic factors such as polymorphisms in key genes presented in inflammatory pathways, apoptosis, 
autophagy and metabolism and drug transportation. 
The main existing challenge results from the difficulty in predicting the disease development along 
the years, which turns the choice of appropriate therapeutic and control of symptoms problematic. 
With the purpose of answering to these questions, we have developed several studies, here 
compiled in this dissertation, that have the main goal of identifying clinical and genetic predictors of 
response to the normally used therapies that allowed the physicians to stratified their patients in order 
to apply a more personalized therapeutic based on individuals genetic profile. 
As main results emerges the identification of genetic polymorphisms in cytokine genes such as 
TNFα, LTα, IL1 e IL6 as associated with disease aggressiveness and development. The high 
consumption of glicids, lipids, saturated, monounsaturated and polyunsaturated fats appears as risk 
factors to greater disease aggressiveness. Clinical predictors such as patient’s age, surgery and 
perianal involvement and genetic predictors like Casp9 and MDR1 gene polymorphisms were 
associated with response to therapy. 
The future for the treatment of Crohn’s disease resides in the investment in pharmacogenetics and 
nutrigenetics studies, such as the studies described here, since they emerge as a benefit to the 
routinely clinical practice that contributes to a therapeutic and nutritional therapy personalized to each 
patient and, therefore, a better quality of life. 
 
 
 
 
Keywords: Crohn’s Disease, Inflammatory Bowel Disease, Pharmacogenetics, Nutrigenetics, 
Personalized medicine. 
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CHAPTER I - INTRODUCTION 
 
 
I.1 CROHN’S DISEASE 
 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of unknown origin that is 
characterized by an uncontrolled inflammatory response in any part of the gastrointestinal tract (GI) 
that is thought to be related to alterations in the gut microbiome in genetically predisposed individuals 
(Cottone & Criscuoli 2011). Until now, there is no cure available and patients go through periods of 
active disease, that may lead to progressive bowel damage and complications as fistulas, abscesses 
and strictures, followed by periods of relapses and remission (Panaccione et al. 2012). 
It can vary from mild to severe and the major symptoms embrace abdominal pain, diarrhea, GI 
bleeding, nausea, weight loss, fever and fatigue. Crohn’s disease can also affect other parts of the 
body like joints, skin, liver and eyes, which are referred as extraintestinal manifestations (EIM).  
The diagnosis is currently based on a combination of clinical presentation, endoscopic appearance, 
surgical findings and radiologic, histologic and serologic criteria (Van Assche et al. 2010).  
Important assessment tools as a CD activity index (CDAI) and Harvey-Bradshaw index (HBI) exist 
for CD symptoms evaluation (Papay et al. 2013). 
The prevalence of CD in Europe varies from 1.522 to 21312 cases per 100 000 individuals (Burisch 
et al. 2013). The incidence of CD is considered variable for different regions and groups of population 
and has been increasing in recent years. It is commonly higher in developed countries, mainly in North 
America and Western Europe and more predominant in urban than rural areas and northern than 
southern areas (Magro et al. 2012) (Burisch et al. 2013). A study by (Shivananda et al. 1996) reported 
that in Portugal between 1991 and 1993 it was estimated a CD incidence of 2.4 per 100 000 subjects. 
It can be developed at any age, but it mainly occurs between ages 20-30 years (Magro et al. 2012). 
For European CD patients, mortality is up to 40% when compared with the general population 
(Colombel et al. 2014) 
To date, it is known that is a lifelong disease that results from the interaction between clinical, 
environmental and genetic factors (Van Assche et al. 2010). 
 
 
I.1.1 CLINICAL AND ENVIRONMENTAL FACTORS 
 
Crohn’s disease is classified as a heterogeneous disease once it presents a variety of phenotypes in 
terms of age of onset, disease location and disease behaviour (Van Assche et al. 2010) (Louis et al. 
2011). Due to this heterogeneity, a classification system named Montreal classification was developed 
based on different phenotypes (Table 1). 
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Table I.1. Montreal classification of Crohn’s Disease. (Adapted from Silverber et al., 2005) 
 
A1- ≤ 16 years 
A2– 17-40 years 
Age at diagnosis 
(A) 
A3- > 40 years 
L1- Terminal ileum 
L2- Colon 
L3- Ileocolon 
Location (L) 
L4- Upper gastrointestinal 
B1- Inflammatory/ nonstricturing and nonpenetrating 
B2- Stricturing Behaviour (B) 
B3- Penetrating 
 
It is also possible to complement disease phenotype analysis based on Montreal classification with 
disease modifiers of location, namely location on upper gastrointestinal that can be divided into L1+L4, 
L2+L4 and L3+L4, and disease modifiers on behaviour with perianal disease that can assume B1p, 
B2p and B3p (Gisbert et al. 2008). 
Several studies have demonstrated that disease location is the clinical feature most associated with 
the disease course, with the terminal ileum location strongly associated with a greater risk of stricture 
and internal penetrating behaviour and with the risk of surgery (Louis et al. 2010). 
Environmental factors such as smoking habits, diet and drugs are pointed as important parameters 
in Crohn’s disease development, but there aren’t enough studies to confirm this for use routinely in 
clinical practice. It is hypothesised that smoking habits and the use of nonsteroidal antiinflammatory 
drugs (NSAIDs) lead to a more permeable mucosa of the intestine and that the introduction of 
antibiotics or occurrence of gastrointestinal infections causes the alteration of bacteria that normally 
lives in the colon (Parkes et al. 2014). 
The most studied environmental factor is smoking and has been reported that not only increases the 
risk to CD, but also aggravates the course of disease (Parkes et al. 2014). 
 
 
I.1.2 IMMUNOLOGY AND GUT MICROBIOME 
 
During intestinal inflammation in CD it has been observed that occurs an improper host immune 
response to intestinal flora (Allez & Lémann 2009). 
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Several studies have been suggesting that the pathogenesis of CD is mostly related to genetic, 
environmental and immunological factors (Chen et al. 2014) (Huebner et al. 2009). In fact, it has been 
shown that CD is a Th1-mediated disease characterized by an excessive Th1-cell activity 
(Hendrickson et al. 2002). 
It has been suggested that increased intestinal permeability may play a role in CD pathogenesis 
(Ardizzone & Bianchi 2002). 
Regarding pathogenic traits, CD patients present in greater number bacteria with proinflammatory 
properties like Escherichia coli in opposition to a more reduced number of Faecalibacterium 
prausnitzii, which have antiinflammatory properties (Colombel et al. 2014). 
Recently, the study of underlying inflammatory processes and the appearance of new biological 
therapies directly targeted to proinflammatory mediators has gained major attention due to its 
important contribution to the future of CD management (D’Haens et al. 2014) (Stappenbeck et al. 
2014). 
Although continuously investigation is on progress on these thematic, the underlying pathogenesis of 
CD remains unclear. 
 
 
 
I.2 GENETIC POLYMORPHISMS 
 
The importance of genetics in CD pathogenesis was demonstrated by strong familial aggregation, 
twin studies and established genetic associations (Rioux et al. 2007). In fact, the data shown in several 
studies in twins strongly supports the importance of the genetic component in this disease, once it was 
demonstrated a significant increase in the concordance of CD in monozygotic twins when compared to 
the existing in dizygotic twins (Peña & Crusius 1998). 
The common use of genome-wide associations (GWA) led to the comprehension of the molecular 
pathways that were determining in CD. These studies allowed the identification of specific 
polymorphisms responsible for individual’s susceptibility to disease and those that can be used as 
therapeutic targets in the development of more effective and safer treatments for CD patients (Budarf 
et al. 2009) (Cho & Weavet 2007). Identified genes conferring disease susceptibility seem to differ 
from those responsible for clinical phenotype determination, such as extent and severity of disease, 
and its response to medical therapy (Ardizzone & Bianchi 2002). 
In the recent years, much progress has been achieved and the discovering and confirmation of 163 
IBD susceptibility genetic regions by the end of 2012 is a proof of that. The nucleotide-binding 
oligomerization domain containing 2 gene (NOD2) on chromosome 16q12, involved in innate 
immunity, was the first identified CD risk gene and continues to be the most proven CD susceptibility 
gene so far, with three variants most usually associated with CD (R702W, G908R and L100fs) (Kabi et 
al. 2012). Up to one third of CD patients carry one of these three allelic variants against 10-15% of the 
normal population (Cummings & Rubin 2006). 
CHAPTER	  I.	  INTRODUCTION	  
	  
	   4	  
The contribution of CD genetics has gain great importance in changing clinical practice once it may 
predict the disease phenotype such as disease location, disease behaviour and the occurrence of EIM 
and the decision of treatment strategies to adopt to each individual (Figure1). 
 
 
 
Figure I.1. Most important susceptibility genes to Crohn’s disease (CD) and its association with 
disease phenotype and response to therapy. (Adapted from Brand 2013) 
 
The most relevant association was described for NOD2 as the most important genetic predictor for 
CD ileal disease, ileal stenoses, fistula and surgery (Xia et al. 2005). Another gene, yet with a weaker 
association than NOD2, significantly associated with ileocolonic disease involvement and stenosing 
disease behaviour was janus kinase 2 gene (JAK2), an important element of the signal transduction 
pathway of several cytokines like interleukin 12 (IL12) and interleukin 23 (IL23) that are involved in CD 
pathogenesis (Xia et al. 2005). 
Greater importance has been paid to the existing variability in efficacy of the therapeutic applied to 
CD patients. It has been shown that this variability is influenced by disease severity, environmental 
factors and genetics factors. It was predicted that 20-95% in variability of drug effects in CD patients is 
due to genetic polymorphisms, with the main gene candidates those encoding for drug receptors, 
metabolizing enzymes, transporters and disease susceptibility genes (Pierik et al. 2006). 
 
 
 
 
 
CHAPTER	  I.	  INTRODUCTION	  
	  
	   5	  
I.2.1 CYTOKINE GENES 
 
One of the most important inflammatory mediators in CD are cytokines and its described genetic 
polymorphisms are very well studied, since it’s though to influence inflammatory response and 
consequently disease susceptibility and/or development (Ardizzone & Bianchi 2002). 
The uncontrolled inflammatory response results from an imbalance between proinflammatory 
cytokines such as interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), interleukin 1 (IL1), 
interleukin 6 (IL6), IL12 and antiinflammatory cytokines like interleukin 1 receptor antagonist (IL1RN) 
(Guidi et al. 2011). Some single nucleotide polymorphisms (SNP) have been already identified as 
associated to CD, particularly IL1β +3953 C/T and -511C/T, TNFα -857 C/T and -308 G/A, 
lymphotoxin alpha (LTα) +252 A/G, IL6 -174 G/C and IL1RN variable number tandem repeat of 86 
base pairs (VNTR) (Waterer & Wunderink 2003). 
Another known CD gene risk is interleukin 23 receptor (IL23R) on chromosome 1p31 (Duraes et al. 
2013) (Brand 2013). It was reported a strong protective effect of the Arg381Gln allele of the IL23R 
against CD developing, contrarily to variants of IL23 gene that conferred increased risk (Budarf et al. 
2009) (Cho & Weavet 2007). The demonstrated genetic association and the proinflammatory role of 
IL23 turn this pathway into a therapeutic target for CD (Cho & Weavet 2007). 
 
 
I.2.2 APOPTOSIS GENES 
 
Much have been speculated about the importance of apoptosis in CD, but recent studies suggested 
that Fas-mediated apoptosis influences CD pathogenesis by inducing gut inflammation, either by 
increased apoptosis of intestinal epithelium or decreased apoptosis of lamina propria lymphocytes 
(Xia et al. 2005). 
The interaction between Fas and its ligand, Fas Ligand (FasL), activates the extrinsic pathway of 
apoptosis that leads to the activation of caspase 8 and the initiation of all of the apoptotic process, 
including the intrinsic apoptotic pathway (Xia et al. 2005). 
One of the most described polymorphism is the FasL -843 C/T, in the promoter and near the local of 
ligation to the CAAT activator protein, with the CC genotype associated with a three times greater 
capacity of ligation to the CAAT protein and, consequently, a three times higher expression of FasL 
(Nagata 1994). 
The Caspase 9 (Casp9) is an apoptosis related protein that forms an apoptosome, after ligation to 
cytochrome C and Apaf-1, which activates caspases 3, 6 and 7. Although its association with the 
apoptotic process, its functionality remains unclear (Krammer et al. 1994). It has been described that 
Casp9 +93C/T polymorphism influenced response to biologic therapy in luminal CD cohort (Hlavatay 
et al. 2005). 
In Crohn’s disease it has been observed that different cells are unresponsive to apoptosis, which 
may represent an underlying genetic defect in lymphocyte and monocyte functioning and justified its 
persistence in sites of intestinal inflammation (Souza et al. 2005). 
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I.2.3 AUTOPHAGY GENES 
 
Autophagy is the homeostatic process, through which cytosol or intracellular organelles are 
sequestered by autophagosomes to be delivered to lysosomes and consequently degraded (Deretic 
2006). This biologic process is involved in protein degradation, antigen processing, regulation of cell 
signalling and several other pathways essential to the initiation and regulation of inflammatory 
response, which suggests that autophagy is likely to have an important role in CD pathogenesis 
(Rioux et al. 2007). 
The GWA studies showed the importance of ATG16L1 and IRGM, autophagic genes, as related to 
CD pathogenesis. The ATG16L1 gene is part of the autophagosome pathway and has been 
associated with the processing of intracellular bacteria (Cho 2008). The ATG16L1 Thr300Ala variant is 
directly associated to CD pathogenesis (Budarf et al. 2009).  
It is important to refer a significant association between the ATG16L1 gene and the NOD2 gene, 
which is known to be a CD risk gene (Márquez et al. 2009). 
In GOIA Study II (Duraes et al. 2013), it was reported that in the Portuguese population a genetic 
profile involving SNPs in three autophagy-related genes, ATG16L1, IRGM and intelectin 1 (ITLN1), 
helps to predict Crohn’s ileal or ileacolonic disease, involvement of the upper digestive tract, response 
to steroids and to biologic therapy. 
 
 
 
I.3 NUTRITION 
 
For the past decades an emerging growing in the incidence and prevalence of IBD has been 
observed, which strongly suggests the importance of environmental factors as triggers for this disease 
(Hou et al. 2014). One of these suggested triggers is dietary patterns, based on the spreading of 
“western” diet high in fat and protein and low in fruits and vegetables and through its influence in 
intestinal inflammation, namely by altering gut microbiome and affecting gastrointestinal permeability 
(Hou et al. 2014). 
 Crohn’s disease is commonly associated with malnutrition and weight loss that results from 
reduction of food intake, inappropriate dietary patterns, inflammatory process and side effects of 
multiple therapies applied in CD treatment. Nowadays, this pattern has become less common due to 
advances in treatment options, greater knowledge of how diet can influence disease course and an 
increased number of patients attaining clinical remission (Hwang et al. 2012). 
 Along the years, several studies have been trying to establish a link between diet and CD 
development, once it is very important that CD patients identify and avoid foods that worsen 
symptoms (Fergunson 2013).  
Distinct associations between fatty acids, higher fruit intake and protein with the development of CD 
have been described, suggesting that they play a protective role against flares (Hou et al. 2014). 
Various dietary components have been proposed to increase the risk of developing or exacerbating 
symptoms of CD. The main macronutrients pointed as prejudicial for CD patients are sugars and fats, 
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particularly saturated, polyunsaturated and trans (Hou et al. 2014). General recommendations also 
suggest reducing high-fiber foods and limit consumption of dairy foods during flares (Fergunson 2013). 
It is commonly observed in CD patients micronutrients deficiencies such as iron, magnesium, zinc, 
calcium and vitamins A, D, K, B6, B9 (folic acid), B12 (cobalamin) and C (L-ascorbic acid). Those 
micronutrients deficiencies lead to important EIM like anemia, bone disease, hypercoagulability, 
wound healing and colorectal cancer risk (Hwang et al. 2012) (Gassul 2003). 
 Studies have demonstrated that CD patients have ω-3 fatty acids deficiencies. These fatty acids are 
known to be involved in immunomodulatory mechanisms in IBD, such as altering proinflammatory 
eicosanoid synthesis, cell membrane fluidity, cell signal transduction, intraluminal bacterial content 
and expression of inflammatory genes such as TNFα, IL1 and IL6 (MacLean et al. 2005). Because of 
this, it’s usually recommended supplemental ω-3 fatty acids as beneficial in treating or preventing 
relapses in CD (MacLean et al. 2005).  
In Europe it has been considered the use of exclusive enteral nutrition with elemental, semi-
elemental and defined formula diets for CD as first line therapy for induction of remission, due to its 
results in mucosal healing, prolong clinical remission and highly favourable safety profile, although its 
use over long periods of time it’s still uncertain (Hou et al. 2014) (Hirai et al. 2013). 
Although all these facts, the identification and use of guidelines based on diet for IBD patients is still 
growing and data on how altering diets can influence disease susceptibility and development are 
limited. 
 
 
 
I.4 THERAPEUTIC 
 
Several pharmacological therapies aimed at controlling intestinal inflammation have been developed 
along the years. 
The treatment goals in CD are not just concerning control of symptoms and GI inflammation, but 
mainly preventing bowel damage, reducing long-term disability and maintaining patients quality of life 
(Papay et al. 2013).  
The treatment of active CD is very complex and approximately 20% of patients do not respond to 
conventional therapy, namely corticosteroids (CS) and immunosuppressors like azathioprine (AZA) 
and methotrexate (MTX) (Orlando et al. 2005). The development of new therapies led to the use of 
chimeric monoclonal antibodies that specifically blockage and neutralise the human tumour necrosis 
factor-a (TNF-a), an important proinflammatory cytokine in bowel mucosal inflammation (Mascheretti 
et al. 2004). 
 
 
I.4.1. THERAPIES FOR CROHN’S DISEASE 
 
Several therapies are used as CD treatment, namely: 
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Aminosalycilates 
The application of aminosalycilates, mainly 5-aminosalicylic acid (5’ASA), has long been used as 
first-line treatment in CD. However, its use as induction and maintenance therapy still remains 
conflicting, once it has been shown that its relative inefficacy may be due to the fact that it only 
addresses mucosal disease and may not have activity in deeper layers of the bowel (Williams et al. 
2011) (Herrlinger & Jewell 2006). 
 
Corticosteroids 
Corticosteroids offer a more efficacious and rapid relief of symptoms in the majority of IBD patients 
(Panaccione et al. 2012). Although most patients initially respond to corticosteroids, after 1 year, 
approximately 25% become steroid-dependent (Gisbert et al. 2009). 
 
Immunosuppressors 
The decision to begin immunosuppressive therapy should rely on the fact that most patients should 
present a chronic active disease course, corticosteroid dependence and resistance and recurring 
flares of CD (Gisbert et al. 2008). It’s also referred for development of complicated disease course, 
presence of perianal fistulising disease and EIM (Wenger et al. 2012). Early introduction of 
immunosuppressive treatment in mild CD patients should be prevented at all cost because of 
overtreatment, unnecessary side effects and therapeutic toxicity (Cosnes et al. 2013). 
 
Biologic therapy 
Monoclonal antibodies that bind to TNFα have revolutionary the management of moderate to severe 
CD that is refractory to conventional therapy (Reenaers 2010). It is known that TNFα affects the 
epithelial barrier, induces apoptosis of the villous epithelial cells and secretes chemokines from the 
intestinal epithelial cells (Cottone & Criscuoli 2011). 
The ideal biologic agent for CD treatment should target a specific event of the inflammatory pathway, 
induce and maintain sustained remission, be well tolerated and do not induce any immunogenicity 
(Reenaers 2010). 
It is recommended that biologic therapy should be use as first-line therapy in patients with 
complicated disease or bowel damage and poor prognostic factors and/or severe disease (Peyrin-
Biroulet et al. 2013). Despite all the successfully treatments with biologic therapy it is important to note 
that one-third of patients will not respond to this therapy, although this percentage may decrease if 
patients begin this type of treatment as early as possible (Panaccione & Ghosh 2010). 
One of the mostly used monoclonal antibodies is Infliximab (IFX), which has proven to be highly 
effective agent in induction and maintenance in patients with refractory luminal and fistulising CD 
(Cottone & Criscuoli 2011). Therapeutic development led to the arrival of Adalimumab (ADA), 
subcutaneously administered, that is effective for the induction and maintenance of therapy in patients 
with moderate to severe CD (Orlando et al. 2012) and Certolizumab pegol (CPZ) that has been shown 
to be effective as induction therapy in patients with moderate to severe CD, offering a rapid treatment 
response and symptom relief (Schreiber 2011).  
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Combined therapy 
The evidence suggests that the early use of biologic therapy, in combination with 
immunosuppressors, culminated in the achievement of a more rapid remission than with conventional 
progression of treatment, with a longer time to relapse, decreased need for treatment with 
corticosteroids, faster reduction in clinical symptoms, decreased inflammatory markers and improved 
mucosal healing (Cottone & Criscuoli 2011) (Colombel 2012). 
Nevertheless, it remains unclear the optimal use of combined therapy, mainly because of doubts 
about immunogenicity, efficacy and safety (Panaccione & Ghosh 2010). 
 
The application of the described therapies is commonly referred as “step-up” therapy, a model 
normally described as a pyramid scheme, with the milder and less toxic therapies at the base of the 
pyramid and the more efficacious and powerful therapies at the top like shown in Figure 2 (Pithadia & 
Jain 2011). 
 
 
 
 
 
 
 
 
Figure I.2. Conventional “step-up” treatment strategy for Crohn’s disease patients. (Adapted from 
Hutfless et al. 2014) 
 
Conventional treatment strategies have focused on induction of a clinical remission using a step-wise 
approach to medical therapy with 5-aminosalicylates, corticosteroids and immunosuppressors, but in 
recent years clinical trials of earlier use of immune-modifying or biologic therapies (or combinations of 
them) have been associated with more rapid remission and improved short- and longer-term 
outcomes (Rubin et al. 2012). 
Several studies have been demonstrating that an early introduction of intensive therapy in patients 
with disabling and/or severe CD of immunosuppressors and/or biologic therapies generates an 
increased probability of mucosal healing and early continuous remission without steroids (Van Assche 
et al. 2010). It’s assumed that when at least two clinical predictors are present in one patient, early 
treatment with azathioprine and/or biologics should be considered (Van Assche et al. 2010). 
The traditional treatment paradigm includes a “step-up” approach of corticosteroids and 
immunosuppressors, with or without biologic agents as severity progresses or patients fail to respond. 
Whereas this approach may be effective in the near term, it may not prevent overall disease 
progression (Tamboli et al. 2011). Within 10 years of diagnosis, more than half of CD patients still 
require surgical resection and within 20 years, approximately 50%–70% of CD patients develop a 
stricturing or penetrating intestinal complication, and the cumulative risk of hospitalization rises to 
nearly 80%. The risk of hospitalization is greater within the first year after diagnosis of CD (32%–83% 
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of patients), with the annual incidence of hospitalizations remaining steady at 20% over the next 5 
years. “Top-down” therapy, with the earlier introduction of biologic agents such as antitumor necrosis 
factor alpha (anti-TNF-α) antibodies, has demonstrated high rates of remission and mucosal healing 
(Tamboli et al. 2011). 
Recent studies of ‘top-down’ versus ‘step-up’ therapy for CD have shown conflicting results. A 
prospective randomized comparison between a step-up regimen with corticosteroids and a top-­‐down 
strategy starting with infliximab showed favorable results for the top-­‐down approach after six months, 
but significance was lost after 12 months (Kruis et al. 2013). A five-year prospective observational 
study concluded that indiscriminate use of biological therapy (‘top-­‐down’ strategy) is not appropriate 
for moderate to severe CD. Indeed, the recent European Crohn's and Colitis Organisation (ECCO) 
management guidelines point out that for selected patients with mild CD, one option is to start no 
active treatment.  
Long-term efficacy, safety and cost are main concerns of risk/benefit assessment of different 
treatment strategies. In step-up approach, infections associated with corticosteroids and lymphomas 
caused by azathioprine are commonly seen adverse events. In top-down approach, serious infections, 
lymphoma and malignancies are side effects of anti-TNF agents and immunosuppressives (Chen et 
al. 2014). 
Nevertheless, the prediction of which approach should be used in each patient depends on a 
combination of clinical parameters, namely disease aggressiveness, serologic markers and individual 
genetic profile, emphasizing the importance of more pharmacogenetic studies in the near future. 
 
 
 
I.5 OTHER INFLAMMATORY BOWEL DISEASES 
 
In addition to Crohn’s disease, Ulcerative colitis (UC) is the other chronic inflammatory disorder that 
completes the known Inflammatory Bowel Diseases group, which is characterised by specific 
phenotype, genetic predisposition, environmental factors and uncontrolled immune response to the 
gut microbiome (Duricova et al. 2014).  
The prevalence of UC in Europe varies from 2.422 to 2.946 cases per 100 000 individuals, whereas 
the incidence for the total European population suggests that may be up to 2.1 million persons (Burish 
et al. 2013). Although considered as “Western” diseases, it is now known that IBD incidence and 
prevalence are rapidly increasing in areas like India, Japan, China and Middle East (Lee et al. 2011) 
(Norgard et al. 2014).  
Ulcerative Colitis specifically presents continuous mucosal inflammation of the colon, rectal bleeding, 
diarrhea and abdominal pain, showing a relapsing and remitting disease course (Louis et al. 2010). 
The disease classification is mainly based in disease location divided in proctitis (E1), left-sided UC 
(distal UC) (E2) and extensive UC (pancolitis) (E3) (Louis et al. 2011). Affects equally both sexes and 
has been shown that first-degree relatives of UC patients have a 10-15 fold risk of developing the 
disease (Dignass et al. 2012). 
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The environmental factor most studied in UC is smoking. In fact, it has been already shown and it is 
well established that occurs a protective effect of smoking against the development of UC (Parkes et 
al. 2014).  
 The dietary guidelines available for UC patients are very similar to the ones for CD patients. It is 
also a disease commonly associated with malnutrition and weight loss resulting from nutritional 
deficiencies, inflammatory process; reduction of food intake; inappropriate dietary patterns and side 
effects of therapy (Hwang et al. 2012). Recommendations emphasized the use of fatty acids, higher 
fruit intake and protein, and alert against the excessive use of sugars and fats, particularly saturated, 
polyunsaturated and trans as well as suggest reducing high-fiber foods and limit consumption of dairy 
foods during flares (Brown et al. 2011). It is commonly observed in UC patients micronutrients 
deficiencies such as vitamin B12, folic acid and especially iron, since iron-deficient anemia due to 
blood loss occurs in up to 80% of these patients (Brown et al. 2011). 
Regarding UC genetics, GWA studies have led to the identification of several susceptibility genes, 
particularly the HLA region, which is the most strongly associated with UC, but also the IL23R gene, 
the DLG5 gene, the JAK/STAT pathway, the MDR1 gene and TLR gene (Dignass et al. 2012) (Brant 
2013). 
Medical treatment comprises mainly 5-aminosalicylates in both induction and maintenance of clinical 
and endoscopic remission, corticosteroids and immunosuppressors, including cyclosporine that is an 
option for severe acute UC if intravenous corticosteroids fail to induce remission (Williams et al. 2011) 
(Rutgeerts et al. 2005) (Lichtenstein & Rutgeerts 2010) (Pierik et al. 2006). It is believed that TNFα 
promotes the inflammatory response in UC patients so it is important to include TNF inhibitors, like the 
approved Infliximab and Adalimumab, that emerges like an alternative to the conventional treatment 
with aminosalicylates, corticosteroids and immunosuppressors when patients do not respond 
(Thorlund et al. 2014). 
Similar to the strategies adopted in the treatment of CD, there is also a “step-up” approach in UC 
treatment normally described in a pyramid scheme with the milder and less toxic therapies at the base 
of the pyramid and the more efficacious and powerful therapies at the top, like shown in Figure 3 
(D’Haens et al. 2014). 
 
                             
 
Figure I.3. Conventional “step-up” treatment strategy for Ulcerative colitis patients. (Adapted from 
Hutfless et al. 2014). 
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Inflammatory bowel diseases present a highly variable clinical course, which complicates diagnosis 
prediction and consequently, the determination of appropriate therapeutic strategies. A major obstacle 
to the introduction of personalized medicine in IBD patients is the lack of applicable clinical, genetic, 
environmental and therapeutical predictors to guide treatment at early diagnosis (Reenaers et al. 
2012). 
 
 
 
I.6 AIMS AND THESIS STRUCTURE 
 
Crohn’s disease is a multifactorial disease of unknown origin, characterized by clinical and genetic 
heterogeneity that has been studied for several years in the pursuit of a better understanding of its 
pathogenesis, clinical management and development of more efficacious and safer therapies for its 
treatment. 
One of the immediate difficulties is the precise characterization of CD patients due to the great 
variability in clinical traits and response to therapeutic. Because of this, and with the purpose of 
facilitate diagnosis and specially improve therapeutic response, we have developed a study based in 
the clinical, genetic and therapeutical component of the disease.  
To achieve our goal we have design a study based in the analysis by Real Time PCR of genetic 
polymorphisms in cytokines, apoptosis and autophagy genes that allow us to stipulate phenotype-
genotype relations and its association with response to therapy conventionally used to treat CD. With 
this in mind, the primary purpose is the establishment of guidelines that leads to the application of 
individualized therapeutic. As main aims we propose: 
1. Study of the association between polymorphisms in the MDR1, IL23R, ATG16L1, Fas, Fas 
Ligand e Casp9 genes and the phenotype parameters such as age at diagnosis, disease 
location, disease behaviour, disease aggressiveness, fistulas and extraintestinal manifestations; 
2. Study of the association between polymorphisms in the MDR1 gene and the response to 
aminosalycilates, corticosteroids and immunosuppressive therapy; 
3. Study of the association between polymorphisms in the Fas, Fas Ligand e Casp9 apoptotic 
genes and the response to biologic therapy; 
4. Study of the association between polymorphisms in the IL23R gene and the response to 
corticosteroids, immunosuppressive and biologic therapy; 
5. Global evaluation of the importance of pharmacogenetics in the management of IBD; 
6. Understanding the relevance of nutrigenetics in IBD management. 
 
The present dissertation summarizes all the results obtained in the past years, where we have been 
developing several studies, namely a study entitled “Doença de Crohn: fatores genéticos e 
nutricionais”, with a scholarship funding by Sociedade Portuguesa de Gastroenterologia  (2006), that 
allowed us to obtain consistent results of the analysis of polymorphisms in cytokines genes as IL1, 
TNFα e IL6 and the influence of the association between the genetic factors and the intake of fats and 
fatty acids in the disease aggressiveness and the “Estudo de farmacogenética nas Doenças 
CHAPTER	  I.	  INTRODUCTION	  
	  
	   13	  
Inflamatórias Intestinais: Doença de Crohn e Colite Ulcerosa” study, with a scholarship funding by 
Grupo de Estudos das Doenças Inflamatórias Intestinais (2009-2012), that permitted the identification 
of associations between genotype-phenotype relations and response to therapeutic normally used in 
IBD and the associations between polymorphisms in inflammatory, apoptosis and autophagy genes 
and response to therapy used to treat IBD. 
For a better understanding and compilation of all of the results and knowledge obtain along the 
several studies, this dissertation is organized in five chapters: 
- In chapter I, Introduction, it’s presented a global view thought to approach all of the important 
themes for the understanding of the work in question and proposed aims; 
- In chapter II, Nutrigenetics, it’s presented one article that approaches the interaction of fat intake 
with polymorphisms in Caspase9, Fas Ligand and PPARgamma apoptotic genes in modulating 
Crohn’s disease activity in a population of 99 individuals with Crohn’s disease and 116 control 
individuals; 
- In chapter III, Pharmacogenetics, it’s presented three articles where the first one is the study of 
clinical and genetic factors that may be used as predictors of response for several therapies in 
Crohn’s disease in 242 CD patients from several participating hospitals from Central Portugal, 
the second one is the study of IL23R polymorphisms that may influence phenotype and 
response to therapy in Ulcerative colitis in 174 patients from several participating hospitals from 
Central Portugal, and the last one reviews the importance of genetics and susceptibility genes in 
IBD and its use as predictors to individualized therapy; 
- In chapter IV, Discussion, it’s summarized all of the results achieved in the different studies 
supported by previous published results from other authors and it’s enlighten all of the main 
assumptions to remember. This analysis is divided into the discussion of clinical and genetic 
associations, nutrition effects on Crohn’s disease patients and, finally, phenotye-genotype 
relations in association with response to therapy;  
- Finally, in chapter V, Final Remarks and Future Perspectives, based on a synopsis of the aims 
and importance of the work made, it’s suggested future study goals and thematic in order to 
pursuit a better understanding of IBD, specially CD, towards the use of pharmacogenetics and 
nutrigenetics as routinely tools for the management of Crohn’s disease. 
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ABSTRACT	  
Inflammatory	   bowel	   diseases	   (IBD),	   Crohn’s	   disease	   (CD)	   and	   ulcerative	   colitis	   (UC),	   are	  
chronic	   intestinal	   inflammatory	   disorders	   whose	   pathogenesis	   isn’t	   fully	   understood	   and	   are	  
defined	  by	  remissions	  and	  exacerbations.	  Until	  nowadays	  there	  are	  no	  medical	  cures	  available.	  
The	   importance	   of	   the	   genetic	   factors	   in	   the	  determination	  of	   susceptibility	   to	   IBD	  has	   been	  
described	  in	  several	  epidemiologic	  and	  linkage	  studies,	  mainly	  through	  the	  use	  of	  genome-­‐wide	  
association	  studies	   (GWAS)	   that	  permitted	   the	  knowledge	  of	  a	  number	  of	   susceptibility	   loci	   to	  
both	  diseases.	  
Once	   that	  many	   inflammatory	  diseases	  share	  common	  risk	  alleles,	   it	  will	  be	  beneficial	   to	  use	  
different	   disease	   pathways	   for	   pharmacogenetic	   studies,	  which	  will	   allow	   the	   development	   of	  
new	  treatments	  more	  effective	  and	  more	  economical	  attractive.	  
The	   purpose	   of	   this	   article	   is	   to	   make	   a	   review	   about	   the	   importance	   of	   genetics	   and	  
susceptibility	  genes	  in	  IBD	  and	  its	  use	  as	  predictors	  to	  individualized	  therapy.	  To	  achieve	  it,	  we	  
will	   approach	   the	   conventional	   therapy	   and	   its	   advantages/disadvantages,	   describe	   genetic	  
susceptibility	   to	   IBD,	   identify	   genetic	   predictors	   to	   response	   to	   therapy	   and	   analyze	   the	  
applicability	  of	  this	  knowledge	  to	  a	  Portuguese	  population	  study	  in	  order	  to	  step	  forward	  to	  the	  
ultimate	  purpose	  of	  personalized	  medicine.	  
	  
KEYWORDS:	   Inflammatory	   bowel	   diseases,	   therapy,	   genetic	   predictors,	   pharmacogenetics,	  
personalized	  medicine.	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INTRODUCTION	  
It	  is	  common	  knowledge	  that	  both	  environmental	  and	  host	  genetic	  factors	  are	  determining	  in	  
inflammatory	  bowel	  diseases	  (IBD)	  susceptibility,	  disease	  behavior	  and	  response	  to	  therapy.1	  
The	   genetic	   basis	   of	   Crohn's	   disease	   (CD)	   is	   clinically	   based	   on	   the	   previous	   described	  
monozygotic	   twin	   concordance	   rate	  of	   almost	  50%	  and	   the	  positive	   family	  history	  association	  
between	  several	  patients.2	  The	  first	  relevant	  discoveries	  were	  the	  mutations	  in	  the	  NOD2	  gene	  in	  
the	   IBD1	   locus	  on	   chromosome	  16	   that	   emphasized	   the	   importance	  of	   innate	   immunity	   in	  CD	  
pathogenesis.2	  Following,	  genome-­‐wide	  association	  studies	  (GWAS)	  presented	  the	  association	  of	  
CD	  and	  autophagy	  genes,	  identifying	  strongest	  associations	  with	  ATG16L1	  and	  IRGM.2	  Regarding	  
Ulcerative	  Colitis	   (UC)	   it	  was	  described	   that	   the	   interleukin-­‐23	   receptor	  gene	   (IL23R)	  and	   the	  
interleukin-­‐12β	   gene	   (IL12B)	   were	   significantly	   associated	   and	   GWA	   studies	   identified	  
associations	  with	  the	  actin-­‐related	  protein	  2/3	  complex	  subunit	  2	  gene	  (ARPC2),	  the	  interleukin-­‐
10	  gene	  (IL10)	  and	  with	  regions	  on	  chromosomes	  1p36	  and	  12q15.3	  
Inflammatory	  bowel	  diseases	  are	  chronic	  relapsing	  diseases,4	  being	  CD	  and	  UC	   the	   two	  main	  
clinical	   presentations	  with	   differences	   regarding	   disease	   extension,	   localization,	   behavior	   and	  
the	  occurrence	  of	  extraintestinal	  manifestations	  (EIM).	  The	  precise	  etiology	  of	  IBD	  is	  unknown	  
but	  both	  environmental	   factors	  and	  genetic	  susceptibility	  are	   involved.5,6	  Nowadays	   it’s	  known	  
that	   extensive	   bowel	   damage	   in	   both	   CD	   and	   UC	   is	   caused	   by	   defects	   in	   the	   innate	   immune	  
system	   that	   consequently	   triggers	   an	   exaggerated	   adaptive	   immune	   response.7,8	   For	   CD	   the	  
localization	   is	   somewhat	   stable,	   but	   the	   disease	   type	   can	   alternate	   over	   time	   from	   an	  
inflammatory	   pattern	   to	   a	   stricturing	   or	   penetrating	   disease,	   causing	   a	   problematic	   disease	  
course.9	   Identifying	   the	   location	  of	  UC	   is	  extremely	  advantageous	   for	  both	  patients	  risk	  profile	  
and	  early	  determination	  of	  the	  most	  effective	  therapy	  suitable	  for	  each	  patient	  phenotype.10,12	  
Guidelines	  for	  CD	  therapeutic	  recommend	  initiating	  treatment	  with	  mesalamine	  and	  systemic	  
corticosteroids,	   pursued	   by	   azathioprine,	   and	   finally	   anti-­‐TNF	   therapies	   for	   patients	   in	  whom	  
conventional	  therapies	  have	  failed.13	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In	  UC	  the	  main	  concern	  is	  to	  induce	  a	  steroid-­‐free	  remission,	  and	  for	  this	  reason,	  its	  important	  
to	  choose	  the	  most	  effective	  treatment	  based	  on	  severity,	  localization	  and	  course	  of	  the	  disease.	  
For	   proctitis,	   is	   recommended	   topical	   therapy	  with	   5-­‐aminosalicylic	   acid	   (5-­‐ASA)	   compounds,	  
while	   for	   more	   extensive	   or	   severe	   disease	   its	   use	   oral	   and	   local	   5-­‐ASA	   compounds	   and	  
corticosteroids.	   In	   case	   of	   non-­‐response,	   patients	   require	   hospitalization	   for	   intravenous	  
steroids	   and	   calcineurin	   inhibitors,	   tumor	   necrosis	   factor-­‐α	   antibodies	   or	   immunomodulators	  
when	  refractory	  occurs.14,15	  
In	   this	   review	   we	   intend	   to	   approach	   thematics	   as	   genetic	   susceptibility	   to	   IBD,	   existent	  
therapeutic,	  genetic	  parameters	  as	  predictors	  for	  therapy	  response	  including	  a	  perspective	  from	  
a	  clinical	  study	  in	  a	  Portuguese	  population	  and,	  finally,	  the	  importance	  of	  genetic	  in	  personalized	  
medicine	  and	  challenges	  for	  the	  future	  to	  come.	  
	  
	  
GENETIC	  SUSCEPTIBILITY	  RELATED	  TO	  IBD	  
Although	  clinical	  parameters	  have	  some	  predictive	  value	  for	  prognosis	  and	  guiding	  treatment	  
strategies	  in	  CD,	  the	  search	  for	  genetic	  polymorphisms	  and	  cytokine	  profiles	  has	  led	  to	  potential	  
predictors	   of	   prognosis	   and	   thus	   the	   identification	   of	   patients	   who	   should	   received	   more	  
aggressive	  therapy	  early	  on	  (top-­‐down).	  	  
Before	   GWAS	   studies,	   the	  NOD2,	   IBD5,	   and	  HLA	   class	   II	  were	   the	  most	   studied	   associations	  
with	  IBD.16,17	  
The	  NOD2	  gene	  associations	  primarily	  described	  demonstrated	  that	  it	  was	  somehow	  related	  to	  
CD	  pathogenesis,	  mostly	  due	  to	  host	  responses	  in	  intracellular	  bacterial	  processing.16	  Recent	  CD	  
associations	  with	  the	  ATG16L1	  gene	  and	  IRGM	  gene	  region	  have	  been	  presented,	  noticing	  that	  
for	   both	   NOD2	   and	   ATG16L1	   genes,	   the	   association	   only	   appears	   related	   to	   CD.16	  With	   great	  
importance	  is	  also	  the	  IL23	  pathway	  in	  IBD	  pathogenesis,	  with	  multiple	  described	  associations	  
within	   the	   IL23R	   gene	   to	   IBD	   and	   more	   moderate	   associations	   with	   the	   IL12B	   and	   PTPN2	  
genes.16	   	  Also	  relevant	  known	  associations	  with	  potentially	  different	  patterns	  of	  relation	   in	  the	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IL23R	  and	  major	  histocompatibility	   complex	   regions	   allows	  new	   insight	   in	   important	  disease-­‐
modifying	  regions	  that	  may	  permit	  the	  establishment	  of	  differences	  between	  CD	  and	  UC.16	  
In	  2006,	  beyond	  NOD2	  and	  IBD5,	  three	  high-­‐density	  GWAS	  and	  one	  non-­‐synonymous	  SNP	  scan	  
identified	  new	  11	  CD	  susceptibility	  loci.18	  Since	  2008	  until	  date,	  it	  was	  reported	  99	  risk	  loci:	  71	  
CD-­‐associated	   loci	   and	   47	   associated	  with	   UC,	  with	   28	   loci	   shared	   between	   the	   two	   diseases,	  
which	   are	   involved	   in	   several	   pathways	   important	   to	   microbial	   recognition,	   autophagy,	  
inflammatory	  response,	  epithelial	  barrier	  maintenance,	  metabolism	  and	  endoplasmic	  reticulum	  
stress	  responses.18,19	  	  
	  
NOD2	  
The	   first	   IBD	   gene,	   NOD2	   (for	   nucleotide-­‐binding	   oligomerization	   domain	   containing	   2;	  
previously	  known	  as	  caspase	  recruitment	  domain	  protein	  15/CARD15),	  located	  on	  chromosome	  
16q12	  within	   the	   IBD1	   region,	  was	   identified	   in	   2001	   through	   association	  mapping	   of	   one	   of	  
these	   linkage	   regions.20	   Three	   mutations	   of	   the	   gene	   (Arg702Trp,	   Gly908Arg,	   and	  
Leu1007fsinsC)	  are	  described	  as	  cause	  for	  reduction	  or	   loss	  of	  NOD2	  function.17,19	   Its	  reported	  
that	  a	  2.4-­‐fold	  increased	  risk	  of	  CD	  occurs	  in	  heterozygous	  carriers	  of	  the	  major	  risk	  allele,	  while	  
a	   17.1-­‐fold	   increased	   risk	   occurs	   in	   homozygous	   or	   compound	   heterozygous	   individuals	   of	  
European	   decent	   and	   no	   association	   has	   been	   observed	   in	   Asian	   or	   sub-­‐Saharan	   African	  
populations.19	   Because	   of	   complexity	   and	   multifactorial	   nature	   of	   disease	   onset,	   associations	  
with	   NOD2	   variants	   simple	   refers	   to	   patients	   with	   an	   earlier	   age	   of	   onset,	   ileal	   location	   and	  
stricture	  formation,	  and	  not	  determining	  of	  disease	  cause.19	  Recent	  studies	  have	  linked	  a	  novel	  
risk	  gene	   interaction	  between	  NOD2	  and	  ATG16L1	   that	  may	  help	   in	   the	  understanding	  of	   IBD	  
susceptibility,	  which	   is	   thought	   to	  be	  due	   to	  a	  dysregulation	  of	  a	  central	  pathway,	   instead	  of	  a	  
dysfunction	  of	  one	  specific	  gene.19	  The	  mechanism	  of	  autophagy	  induction	  by	  NOD2	  that	  can	  be	  
observed	   in	  multiple	   cell	   types,	   such	   as	   epithelial	   cells,	   depends	   on	   ATG16L1	   expression	   and	  
relies	  on	  the	  autophagic	  response	  initiated	  by	  ATG16L1	  existing	  in	  the	  bacterial	  entry	  sites	  in	  the	  
plasma	  membrane.19	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In	  the	  IBD5	  risk	  haplotype	  was	  identified	  within	  a	  larger	  linkage	  region	  on	  chromosome	  5q31,	  
single	  nucleotide	  polymorphisms	   (SNPs)	   genes	   from	  prolyl	  4-­‐hydroxylase	   (P4HA2),	   interferon	  
regulatory	   factor	   1	   (IRF1)	   and	   organic	   cation	   transporter	   (OCTN)	   1	   and	   OCTN2,	   but	   further	  
studies	  are	  needed.3	  
	  
Interleukin	  23	  receptor	  (IL23R)	  
IBD	   susceptibility	   has	   been	   associated	  with	   several	   genes	   in	   the	   Th17	   pathway,	   with	  major	  
focus	   on	   the	   IL23R	   gene	   on	   chromosome	   1p31,	   due	   to	   its	   significantly	   high	   association	   with	  
disease	  development	  and	  involvement	  in	  other	  chronic	  inflammatory	  diseases.21	  
Also	  the	  importance	  of	  the	  IL23	  pathway	  has	  been	  emphasized	  by	  its	  associations	  with	  variants	  
in	   IL12B,	   which	   encodes	   the	   p40	   subunit	   shared	   between	   IL12	   and	   IL23,	   CD	   and	   UC	  
susceptibility	  and	  several	  other	  components	  of	  the	  Th17	  pathway,	  namely	  STAT2	  and	  JAK3	  that	  
are	   also	   associated	  with	  UC,	   the	   chemokine	   receptor	  CCR6	  and	   co-­‐stimulatory	  molecule	   ICOS-­‐
L27.18	  
Major	  attention	  has	  also	  been	  pointed	  to	  the	  IL23/IL12	  because	  of	  its	  determining	  role	  in	  naïve	  
T	  cells	  differentiation	  into	  effector	  Th1	  cells	  (driven	  by	  IL12)	  or	  Th17	  cells	  (driven	  by	  IL23).18	  
The	   genome	   wide	   association	   study	   by	   Duerr	   et	   al	   presented	   significantly	   important	  
associations	  between	  variants	  in	  the	  IL23R	  gene	  and	  CD,	  which	  allowed	  the	  identification	  of	  an	  
uncommon	   coding	   variant,	   rs11209026	   (Arg381Gln),	   that	   confers	   strong	   protective	   effect	  
against	   CD.22	   These	   findings	   are	   interesting	   due	   to	   the	   participation	   of	   IL23	   in	   the	   IL23/IL17	  
axis,	   its	   influence	  as	  a	  proinflammatory	  mediator	  and	  the	  possibility	  of	   its	  use	  as	  a	  therapeutic	  
target	  of	  autoimmune	  and	  chronic	  inflammatory	  diseases	  such	  as	  CD.22	  
Unlike	  NOD2,	  IL23R	  variants	  don’t	  present	  an	  association	  with	  CD	  behavior	  and	  location	  and	  it	  
haven’t	   been	   reported	   that	   the	   IL23R	   genotype	   influenced	   age	   of	   onset,	   need	   for	   surgery	   or	  
association	  with	  family	  history.22	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Apoptosis	  
The	  Fas	  gene,	  in	  the	  chromosome	  10q24.1,	  presents	  a	  single	  nucleotide	  substitution	  at	  the	  -­‐670	  
position	  that	  probably	  exerts	  an	  effect	  on	  the	  level	  of	  transcription	  of	  the	  Fas	  protein	  due	  to	  its	  
location	   at	   the	   consensus	   sequence	   site,	   the	   gamma	   interferon	   activation	   site	   (GAS),	   that	  may	  
bind	  to	  transcription	  factors	  such	  as	  signal	  transducers	  and	  activator	  of	  transcription	  (STAT).23	  
This	   gene	   is	   a	   member	   of	   the	   tumor	   necrosis	   factor	   superfamily,	   is	   possibly	   involved	   in	  
autoimmune	  diseases	  and	  inflammatory	  disorders	  and	  its	  described	  as	  a	  mediator	  of	  apoptosis	  
when	  cross-­‐linked	  with	  agonistic	  anti-­‐Fas	  antibody	  or	  Fas	  ligand	  (FasL).23	  
FasL	  (1q23)	  is	  a	  key	  apoptosis	  inducing	  ligand	  of	  the	  TNF	  family	  of	  death	  factors.24	  It	  has	  been	  
pointed	  a	  threefold	  increased	  binding	  capacity	  to	  the	  CAAT	  enhancer	  protein	  by	  the	  carriers	  of	  
the	  C	  allele	  of	  FasL	  -­‐843C/T	  polymorphism,	  and	  consequently	  a	  threefold	  higher	  expression	  of	  
FasL,	   leading	   to	   an	   increase	   of	   active	   cells	   expressing	   Fas	   apoptosis.	  For	   these	   reasons,	   a	   less	  
severe	  phenotype	  due	  to	  a	  more	  susceptibility	  to	  apoptosis	  will	  occur	  in	  wild	  type	  carriers.24	  
Deregulation	   of	   caspase	   activity	   has	   been	   correlated	  with	   several	   human	   diseases,	   including	  
IBD	  and	  colorectal	  cancer,	  namely	  caspase-­‐8	  that	  controls	  the	  death	  of	  intestinal	  epithelial	  cells	  
in	   patients	   with	   Crohn’s	   disease	   and	   appears	   to	   be	   involved	   in	   mucosal	   inflammation	   and	  
caspase-­‐9	  involved	  in	  the	  sequential	  activation	  of	  caspases	  determining	  in	  cell	  apoptosis.25	  	  
Peroxisome	  proliferator-­‐activated	  receptor	  gamma	  (PPARG)	  (3p25)	  encodes	  a	  member	  of	  the	  
peroxisome	   proliferator	   activated	   receptor	   (PPAR)	   subfamily	   of	   nuclear	   receptors,	   is	  
responsible	  for	  the	  inhibition	  of	  NFkB	  activity	  and	  their	  polymorphisms	  were	  related	  to	  Crohn’s	  
disease.24	  	  
It	   has	   been	   described	   a	   polymorphism	   in	   the	   PPARG	   gene,	   exon	   1	   (CCA-­‐GCA,	   producing	   a	  
Pro/Ala	   substitution	   at	   codon	   12).	   This	   described	   conformational	   change	   in	   the	   protein	   is	  
associated	  with	   a	  more	   aggressive	   and	   active	   phenotype	   in	   the	  wild	   type	   carriers,	  which	   also	  
present	  a	  less	  inhibition	  of	  NFkB	  pathway.24	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Autophagy	  
In	  2007,	  a	  2-­‐fold	  disease	  risk	  increases	  in	  individuals	  homozygous	  for	  the	  risk	  allele	  of	  a	  SNP	  in	  
the	  coding	   region	  of	   the	  ATG16L1	  gene	   (rs2241880)	  was	   identified	  by	  GWAS	  and	  was	   further	  
reported	   that	   the	   linkage	  of	   this	   variant	   to	   IBD	   is	  more	   significantly	   for	  CD	  patients	  with	   ileal	  
disease.19	  	  
Other	   discoveries	   were	   immunity-­‐related	   guanosine	   triphosphatases	   (IRGs),	   with	   two	   SNPs	  
(rs13361189	  and	  rs4958847)	  flanking	  the	  coding	  region	  of	  IRGM,	  that	  are	  an	  important	  family	  
of	   proteins	   involved	   in	   the	   elimination	   of	   different	   intracellular	   pathogens	   in	  most	  mammals,	  
ULK1,	   presenting	   a	   single	   identified	   SNP	   (rs12303764)	   significantly	   associated	   with	   CD,	   is	   a	  
component	  of	  an	  essential	  protein	  complex	  involved	  in	  autophagy	  initiation	  and,	  finally	  LRRK2	  
(leucine-­‐rich	   repeat	  kinase	  2),	  with	  a	  CD-­‐associated	  SNP	   (rs1175593)	   located	  upstream	  of	   the	  
coding	   sequence	   of	   LRRK2,	   is	   an	   important	   participant	   in	   the	   autophagic	   equilibrium	  
maintenance	  and	  is	  near	  two	  relevant	  autophagy	  proteins	  (p62	  and	  LC3).19	  
It	  has	  been	  approached	  in	  different	  studies	  the	  importance	  of	  ATG16L1	  as	  a	  risk	  locus,	  mainly	  
through	   the	   analysis	   of	   its	   polymorphisms	   interactions	   with	   NOD2	   and	   IL23R	   susceptibility	  
variants,	  once	   it	  hasn’t	  been	  quiet	  understood	   if	   it	  depends	  on	  NOD2	  or	   IL23R	  status	  or	   it	   just	  
occurs	  for	  particular	  IBD	  subgroups.26	  
Recently,	   it	  also	  has	  been	  reported	  that	  the	  risk	  variant	  of	  ATG16L1	  is	  important	  to	  IL1B,	  IL6	  
and	  TNFA	  production	   in	  CD	  and	   influences	  the	   induction	  of	  autophagy,	  specifically	  after	  NOD2	  
engagement.27	   It	   was	   also	   demonstrated	   that	   it	   is	   possible	   to	   predict	   response	   to	   anti-­‐TNF	  
therapy	   in	   patients	   with	   CD	   through	   gene	   polymorphisms,	   once	   it	   has	   been	   confirmed	   that	  
patients	  with	  mutated	  NOD2/ATG16L1-­‐combined	  genotypes	  are	  more	   frequently	  submitted	  to	  
an	  enhanced	  anti-­‐TNF	  therapy.27	  
	  
Other	  polymorphisms	  
The	  occurrence	  of	  an	  enhanced	  chronic	  inflammatory	  response	  during	  the	  development	  of	  CD	  
has	  led	  to	  the	  identification,	  through	  genetic	  mapping	  studies,	  of	  several	  polymorphisms	  in	  the	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TNFA	  gene	  and	  the	  IL1	  gene	  cluster.28	  The	  TNFA	  gene,	  on	  chromosome	  6	  in	  a	  region	  containing	  
the	  IBD3	  locus,	  present	  some	  polymorphisms	  in	  the	  TNFA	  promoter	  that	  have	  been	  suggested	  as	  
implicated	  in	  CD	  susceptibility,	  such	  as	  TNFA	  -­‐308	  which	  is	  the	  strongest	  association	  described,	  
TNFA	  -­‐238,	  TNFA	  -­‐376,	  and	  TNFA	  -­‐1031	  that	  play	  a	  role	  in	  the	  transcription	  rate	  of	  TNFA.29	  	  
Studies	  in	  lymphotoxin-­‐α,	  namely	  LTA	  +250,	  a	  G	  to	  A	  transition	  in	  the	  first	  intron	  of	  LTA,	  have	  
suggested	  an	  association	  with	  increased	  TNFA	  production	  both	  in	  vitro	  and	  in	  vivo	  for	  carriers	  of	  
the	   A	   allele,	   but	   further	   conclusions	   are	   needed.	   This	   locus	   has	   been	   pointed	   out	   due	   to	   its	  
relation	  with	  many	  inflammatory	  conditions.	  An	  association	  of	  linkage	  disequilibrium	  has	  been	  
verified	  between	  the	  TNFA	  -­‐308G	  allele	  and	  the	  LTA	  +250	  A	  allele.29	  
Interleukin	  1	  (IL1),	  a	  potent	  proinflammatory	  cytokine,	  belongs	  to	  the	  IL1	  family	  that	  includes	  
the	   agonists	   IL1A	   and	   IL1B	   and	   the	   IL1	   receptor	   antagonist	   (IL1RA),	  with	   IL1B	   crucial	   in	   the	  
process	  of	  inflammatory	  response.28,	  29	  The	  studied	  polymorphism	  IL1B-­‐511	  C/T	  and	  the	  IL1RA	  
variable	  number	  of	  86-­‐pb	  tandem	  repeats	  (VNTR)	  alleles,	  are	  associated	  with	  increased	  levels	  of	  
IL1B	  production,	  which	  suggest	  a	  role	  in	  the	  development	  of	  IBD.28	  
Interleukin	   6	   (IL6)	   is	   a	   multifunctional	   cytokine	   involved	   in	   inflammatory	   response	   and	  
differentiation	  and	  activation	  of	  macrophages	  and	  T	  cells	  that	  presents	  several	  SNPs	  within	  the	  
promoter,	  with	  the	  most	  studied	  suggesting	  that	  the	  wild-­‐type	  carriers	  of	  G	  allele	  of	  IL6	  -­‐174	  C/G	  
polymorphism	  possesses	  an	  enhance	  production	  of	  IL6	  compared	  with	  the	  other	  carriers.29,30	  
Currently	  major	   focus	  has	  been	  driven	  on	   the	  multidrug	   resistance	  1	   (MDR1)	  gene,	  which	   is	  
composed	  of	  28	  exons	  and	   is	  209	  kilobases	   in	   length	  with	  29	  SNPs	  described,31	  with	   the	  most	  
relevant	   SNPs	  known	  being	   the	  C3435T	   in	  exon	  26	  and	  G2677T/A	   in	  exon	  21.	  The	   latter	   SNP	  
originates	   2	   distinct	   amino	   acid	   changes,	   namely	   893Ser	   (G2677T)	   or	   the	  much	   rarer	   893Thr	  
(G2677A).31,32	   These	   two	   SNPs	   are	   thought	   to	   be	   important	   in	   determination	   of	  UC	   extension,	  
like	   has	   been	   confirmed	   by	   Ho	   et	   al.,	   CD	   severity	   and	   susceptibility	   to	   IBD,	   once	   it	   has	   been	  
reported	   that	   they	   may	   lie	   in	   linkage	   disequilibrium.31,32,33	   It	   has	   been	   emphasized	   the	  
importance	  for	  a	  role	  of	  the	  MDR1	  gene	  in	  IBD	  pathogenesis,34	  since	  encodes	  the	  ATP-­‐dependent	  
membrane	  efflux	  transporter	  P-­‐glycoprotein-­‐1	  (PgP),	  whose	  gene	  product	  pgp-­‐170	  when	  highly	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expressed	   in	   intestinal	   epithelium	   plus	   its	   constitutive	   levels	   in	   the	   gut	   suggests	   a	   protection	  
against	  xenobiotics,	  including	  bacterial	  products	  and,	  finally,	  due	  to	  its	  location	  within	  a	  region	  
of	  suggestive	  IBD	  linkage	  on	  chromosome	  7q.32,34	  	  
	  
Analysis	  of	  susceptibility	  genes	  in	  a	  Portuguese	  population	  
Important	   genetic	   polymorphisms	   in	   a	   variety	   of	   antigen	   recognition	   pathways,	  
proinflammatory	  cytokines	  and	  antiinflammatory	  cytokines	  have	  been	  identified	  because	  of	   its	  
influences	  on	  the	  inflammatory	  response.29	  
Accordingly,	   major	   attention	   has	   been	   paid	   to	   agents	   able	   to	   reduce	   the	   secretion	   of	  
proinflammatory	  cytokines	  in	  the	  research	  for	  the	  treatment	  of	  this	  disease.	  In	  our	  study30,	  we	  
have	  examined	  in	  116	  controls	  and	  99	  patients	  with	  CD,	  seven	  SNPs	  in	  IL1,	  TNFA,	  LTA	  and	  IL6	  
genes	   for	   its	   influence	   in	   modifying	   the	   susceptibility	   for	   CD	   and	   disease	   activity	   and	   we	  
concluded	  that	  wild-­‐type	  carriers	  of	  G	  allele	  for	  the	  IL6	  −	  174G/C	  polymorphism	  had	  a	  six-­‐fold	  
higher	  risk	  for	  CD,	  whereas	  the	  carriers	  of	  T	  allele	  for	  the	  TNFA	  −	  857C/T	  polymorphism	  were	  
associated	  with	  more	  active	  disease.30	  
Other	  fundamental	  mechanism	  that	  occurs	  in	  CD	  is	  resistance	  to	  apoptosis,	  namely	  of	  T-­‐cells,	  
which	   certainly	   contributes	   to	   perpetuate	   inflammation	   in	   the	   intestinal	   mucosa.	   For	   these	  
reason	  is	  suspected	  that	  SNPs	  in	  various	  genes,	  namely	  apoptotic	  ones,	  may	  explain	  not	  only	  the	  
heterogeneous	   phenotypes	   but	   also	   the	   different	   responses	   to	   similar	   treatments.	   	   In	   our	  
study24,	   Polymerase	   Chain	   Reaction	   (PCR)	   and	   Restriction	   Fragment	   Length	   Polymorphism	  
(RFLP)	   techniques	   were	   used	   to	   analyze	   CASP9	   +93C/T,	   FasL	   -­‐843C/T,	   PPARG	   +161C/T	   and	  
Pro12Ala	   SNPs	   in	   99	   patients	   with	   CD	   and	   116	   healthy	   controls.	   We	   didn’t	   observe	   any	  
significant	  differences	  in	  odds	  ratio	  concerning	  the	  risk	  of	  developing	  CD	  or	  predisposition	  for	  a	  
more	  active	  phenotype,	  as	  well	  as	  no	  significant	  association	  between	  SNPs	  analyzed	  and	  disease	  
location,	  phenotype,	  age	  of	  disease	  onset	  and	  other	  characteristics	  of	  disease.24	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THERAPEUTIC	  IN	  INFLAMMATORY	  BOWEL	  DISEASES	  
The	  big	  challenge	  clinicians	  face	  when	  treating	  IBD	  patients	  is	  that	  the	  course	  of	  the	  disease	  in	  
the	  years	  following	  diagnosis	  is	  difficult	  to	  predict.	  For	  this	  reason,	  the	  main	  goals	  to	  attain	  with	  
the	  therapeutic	  are:	  relief	  of	  the	  symptoms,	  upgrade	  of	  the	  patient’s	  quality	  of	  life,	  maintenance	  
of	  the	  nutritional	  status,	  deep	  remission	  and	  mucosal	  healing.35	  Several	  studies	  are	  identifying	  a	  
range	  of	  clinical,	  serologic,	  and	  genetic	  predictors	  that	  might	  be	  able	  to	  solve	  this	  question	  in	  the	  
future.36	  
At	   present,	   however,	   clinicians	  must	   select	   treatments	   based	   on	   clinical	   criteria	   and	   on	   the	  
existent	  therapies,	  namely:	  
Aminosalicylates	  
Mesalazine	   [5-­‐aminosalicylic	   acid	   (5-­‐ASA)]	   is	   mostly	   used	   for	   the	   treatment	   of	   mild	   to	  
moderate	  ulcerative	  colitis,	  which	  embraces	  the	  majority	  of	  patients	  with	  this	  disease,	  while	  for	  
CD	  it	  is	  reported	  a	  much	  more	  limited	  role.11	  This	  first	  line	  of	  treatment	  has	  been	  used	  over	  30	  
years	   in	   the	   treatment	   of	   IBD,	   once	   it	   is	   a	   highly	   effective,	   safe,	   and	  well-­‐tolerated	   drug.10,11,37	  
Over	   the	   years	   several	   formulations	   have	   been	   developed	   and	   nowadays	   exists	   as	   oral	  
formulations	  that	  differ	  in	  their	  delivery	  mechanisms	  and	  newer	  drugs	  that	  allow	  direct	  release	  
in	   specific	   regions	   of	   the	   gastrointestinal	   tract	   allowing	   a	   more	   convenient	   dosing	   form	   and	  
schedule.11	  
	  
Corticosteroids	  
Corticosteroids	   (CS)	   are	   potent	   inhibitors	   of	   T	   cell	   activation	   and	   cytokine	   secretion,	   which	  
leads	  to	  its	  use	  as	  the	  first-­‐line	  conventional	  therapy	  for	  patients	  with	  active	  CD	  of	  moderate	  to	  
severe	  activity	  with	  an	  efficacy	  range	  from	  48%	  to	  92%.38,39,40	  It	  has	  been	  reported	  a	  prolonged	  
steroid	  response	  in	  44%	  of	  patients	  with	  CD,	  steroid	  dependency	  in	  36%,	  and	  steroid	  refractory	  
in	   20%,	   while	   failure	   to	   response	   leads	   to	   indication	   for	   surgery	   in	   as	   many	   as	   20%	   of	   UC	  
patients	   and	   approximately	   50%	   of	   CD	   patients.38,40,41As	   side	   effects	   it	   has	   been	   referred	  
systemic	  action	  and	  inhibition	  of	  endogenous	  adrenal	  function.39	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Immunossupressors	  
Thiopurine	  drugs,	  azathioprine	  (AZA)	  and	  mercaptopurine	  (MP)	  are	  the	  principally	  treatment	  
for	  steroid-­‐dependent	  CD,	  due	  to	  its	  efficacy	  in	  maintaining	  remission	  of	  the	  disease	  induced	  by	  
steroids.42	   It	   was	   also	   disclosed	   a	   clear	   steroid	   sparing	   effect	   in	   active	   or	   quiescent	   CD	   with	  
AZA⁄MP	   therapy,	   however	   only	   40%	   to	   50%	   of	   patients	   achieve	   a	   complete,	   steroid-­‐free	  
remission	  with	   AZA.42	   The	   effectiveness	   of	   thiopurine	   therapy	   in	   UC	   and	   CD	   is	   still	   uncertain,	  
because	  of	  the	  limited	  number	  of	  studies	  existing	  and	  the	  knowledge	  that	  surgical	  cure	  of	  UC	  is	  
theoretically	  possible.43	  
Other	   immunosupressors	   have	   been	   used	   when	   thiopurines	   fail,	   namely,	   methotrexate,	  
effective	   for	   induction	  and	  maintenance	  of	  remission;	  cyclosporine	  IV,	  with	  good	  results	   in	  the	  
treatment	   of	   corticoresistant	   UC	   patients,	   with	   variable	   remission	   rates	   from	   50-­‐80%,	  
nevertheless	  it’s	  necessary	  to	  combine	  with	  AZA	  or	  6-­‐MP	  for	  maintenance	  of	  remission	  up	  until	  
5	   years	   in	   60%	   of	   the	   cases	   and	   finally,	   tacrolimus,	   with	   a	   mechanism	   of	   action	   and	   toxicity	  
similar	   to	   cyclosporine,	   but	   more	   powerful,	   presents	   rates	   of	   efficacy	   in	   the	   treatment	   of	  
corticoresistant	  UC	  patients	  nearly	  as	  the	  same	  as	  cyclosporine	  and	  it’s	  not	  applicable	  in	  CD.	  
	  
Biologics	  
The	  realization	  of	  the	  importance	  of	  TNF	  in	  the	  pathogenesis	  of	  CD	  has	  lead	  to	  the	  appearance	  
of	   biologic	   therapy.5,44	   These	   knowledge	   pointed	   to	   the	   development	   of	   biological	   agents	   for	  
treating	   IBD	   capable	   of	   targeting	   a	   specific	   event	   of	   the	   inflammatory	   cascade,	   induce	   and	  
maintain	  a	  sustained	  remission,	  be	  well	  tolerated	  and	  induce	  no	  immunogenicity.4	  The	  anti-­‐TNF	  
therapy	  commonly	  used	  reduces	  reliance	  or	  dependence	  on	  corticosteroid-­‐	  based	  therapies	  and	  
avoids	  corticosteroid-­‐	  associated	  adverse	  effects.44	  
Currently,	   there	   are	   four	   anti-­‐TNF	   agents	   (infliximab,	   adalimumab,	   certolizumab	   pegol	   and	  
golimumab)	  approved	  by	  the	  US	  Food	  and	  Drug	  Administration	  (FDA)	  and	  European	  Medicines	  
Agency	  (EMA)45	  for	  use	  in	  patients	  with	  moderate	  to	  severe	  CD	  for	  whom	  conventional	  therapy	  
has	   failed.	   46	   Infliximab	   (IFX),	   the	   first	   anti-­‐TNF	   agent	   developed,	   is	   a	   chimeric	  mouse/human	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monoclonal	  IgG1	  antibody	  composed	  of	  75%	  human	  and	  25%	  murine	  sequences	  characterized	  
by	  its	  high	  specificity	  for	  and	  affinity	  to	  TNFA,	  that	  neutralizes	  the	  biologic	  activity	  of	  TNFA	  by	  
inhibiting	   the	   binding	   with	   its	   receptors.47	   Adalimumab	   (ADA)	   is	   a	   fully	   human	   recombinant	  
IgG1	   monoclonal	   antibody	   against	   TNFA	   that	   appears	   as	   an	   alternative	   for	   patients	   loosing	  
response	  to	  infliximab,	  with	  its	  use	  approved	  for	  luminal	  CD.	  This	  therapy	  major	  advantage	  for	  
UC	  treatment	  is	  its	  use	  as	  a	  subcutaneous	  drug,	  which	  is	  very	  important	  principally	  for	  patients	  
with	   difficult	   venous	   access.47	   Certolizumab	   pegol	   (CDP-­‐870)	   (CPZ),	   therapy	   subcutaneously	  
administered,	   is	   a	   pegylated	   humanized	   fragment	   antigen	   binding	   (Fab)	   that	   binds	   TNFA.33	  
Golimumab	   (Simponi®)	   is	   a	   relatively	   new	   human	   monoclonal	   anti-­‐TNF	   IgG1	   antibody,	   that	  
emerges	  as	  an	  important	  new	  subcutaneous	  therapeutic	  option	  for	  the	  treatment	  of	  moderately	  
to	  severity	  active	  UC	  in	  adults.45	  
Since	  biologics	  are	  frequently	  given	  to	  patients	  refractory	  to	  former	  treatments,	  it	  is	  frequently	  
observed	   the	  development	  of	  an	  antibody	  response	  against	  biological	  drugs	  due	   to	  cumulative	  
toxicities,	  with	  the	  immunogenicity	  different	  for	  each	  drug.7,48	  	  
	  
Combined	  Therapy	  
Data	  now	  show	  that	  combined	  therapy	  with	  an	  anti‑TNF	  agent	  and	  an	  immunosuppressant	  is	  
the	   most	   effective	   strategy	   for	   treating	   CD.36,49	   However,	   it	   is	   reasonable	   to	   propose	   that	   a	  
patient	  with	  mild	   disease	   and	  no	   criteria	   that	  would	   predict	   increased	  disease	   severity,	   could	  
likely	  be	  treated	  effectively	  with	  a	  less	  intensive	  strategy.36	  
The	   goal	   of	   combined	   therapy	   in	  patients	  with	  CD	   is	   to	   induce	  both	  deep	   remission	   and	   full	  
healing	   of	   the	   transmural	   inflammatory	   process	   that	   occurs	   in	   CD	   in	   order	   to	   avoid	  
complications	   of	   CD,	   surgeries	   and	   disability	   linked	   to	   surgery.36	   Unfortunately,	   it	   is	   still	  
debatable	   long-­‐term	   safety,	   namely	   opportunistic	   infections	   or	   increased	   risk	   for	   certain	  
neoplasms.48	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GENETIC	  PARAMETERS	  AS	  PREDICTORS	  FOR	  THERAPY	  RESPONSE	  
The	  clinical	  course	  of	  CD	  and	  UC	  differs	  enormously	  between	  patients	  which	  is	  problematic	  to	  
the	   design	   of	   the	   treatment,	   although	   there	   are	   some	   known	   clinical	   parameters	   that	   help	   to	  
predict	   a	   mild	   or	   more	   severe	   outcome,	   however	   they	   are	   variable	   over	   time	   and	   very	  
subjective.50	  	  
Genetic	  markers	  are	  emerging	  as	  powerful	  tools	  for	  patients	  stratification	  once	  they	  are	  stable	  
over	  time	  and	  not	  suitable	  for	  subjective	  interpretation,	  although	  further	  studies	  are	  needed	  for	  
its	  use	  in	  a	  regular	  basis.50	  
Recent	  studies	  have	  highlighted	  the	  associations	  between	  genetics	  and	  clinical	  features	  of	  IBD,	  
namely	   disease	   location,	   behavior,	   natural	   history	   and	   response,	   and	   side	   effects	   of	   drug	  
therapy.51	  
	  
Pharmacogenetics	  and	  genetic	  parameters	  
Pharmacogenetics	   permits	   not	   only	   the	   explanation	   of	   interindividual	   variability	   in	   drug	  
response,	   but	   also	   prediction	   of	   efficacy	   and	   adverse	   drug	   events	   in	   different	   patients.52	   Its	  
ultimate	   goal	   is	   the	   recognition	   of	   genetic	   predictors	   of	   drug	   response	   with	   the	   purpose	   of	  
development	  of	  prospective	  genetic	  tests	  that	  permit	  the	  identification	  of	  patients	  at	  risk	  of	  non-­‐
response	  or	  of	  developing	  an	  adverse	  effect	  before	   the	   initiation	  of	   the	   treatment,	   that	  usually	  
results	  from	  allelic	  variants	  in	  genes	  involved	  in	  the	  uptake,	  distribution,	  metabolism,	  transport,	  
receptor	  and	  target	  of	  the	  drug.	  53,54	  	  
The	   major	   focus	   in	   pharmacogenetics	   research	   has	   been	   on	   allelic	   variants	   in	   drug-­‐
metabolizing	  enzymes	  (DMEs).52,54	  
	  
Drug-­metabolizing	  enzymes	  (DMEs).	  
During	   the	   course	   of	   the	   disease	   the	   majority	   of	   CD	   patients	   is	   treated	   with	  
immunossupressors,	   being	   most	   commonly	   used	   azathioprine	   and	   6-­‐mercaptopurine	   and	  
methotrexate	   less	  commonly,	  although	  is	  observed	  wide	  variability	   in	   interindividual	  response	  
in	   terms	   of	   efficacy	   and	   toxicity.53	   For	   these	   reasons,	   emphasis	   has	   been	   made	   in	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pharmacogenetic	  research	  that	  aimed	  at	  predicting	  response	  to	  treatment,	   in	  order	  to	  describe	  
individualizing	  drug	  type	  and	  dose	  for	  each	  patient,	  with	  thiopurine	  analogues	  studies	  being	  the	  
ones	  with	  most	  relevant	  results.53	  It	  is	  known	  that	  after	  absorption	  AZA	  is	  rapidly	  converted	  to	  
6-­‐MP	   by	   a	   nonenzymatic	   reaction,	   where	   three	   enzymes	   compete	   for	   its	   metabolization:	  
hypoxanthine	   guanine	   phosphoribosyltransferase	   initiates	   the	   production	   of	   6-­‐thioguanine	  
nucleotides	   (6-­‐TGNs),	   involved	   in	   the	   therapeutic	  and	   toxic	  hematologic	  effects	  of	   thiopurines,	  
whereas	   xanthine	   oxidase	   (XO)	   and	   thiopurine	   S-­‐methyltransferase	   (TPMT)	   control	   the	  
production	   of	   6-­‐TGNs	   by	   converting	   6-­‐MP	   to	   6	   thioruric	   acid	   and	   6-­‐methylmercaptopurine,	  
respectively.51	  	  
The	   enzyme	   TPMT	   that	   metabolizes	   azathioprine	   presents	   two	   wild-­‐type	   TPMT	   alleles	  
(TPMT*1	  and	  TPMT*1S)	  and	  16	  variant	  alleles	  with	  low	  enzymatic	  activity	  (TPMT*2,	  *3A,	  *3B,	  
*3C,	  *3D,	  *4-­‐15)	  described,	  with	  mutations	  on	  its	  gene	  resulting	  in	  lower	  TPMT	  enzyme	  activity.6	  	  
In	   clinical	   practice,	   its	   commonly	   genotyped	   TPMT	   variants	   and	   measured	   TPMT	   enzyme	  
activity	   with	   the	   purpose	   of	   identifying	   patients	   with	   high	   TPMT	   activity	   that	   metabolize	   6-­‐
mercaptopurine	   to	   6-­‐methyl-­‐MP	   and	   therefore	  may	   be	   resistant	   to	   treatment	  with	   thiopurine	  
drugs,	  once	  genotypes	  do	  not	   fully	  correlate	  with	   the	  enzyme	  activity,	  especially	   in	   the	  case	  of	  
wild-­‐type	   (some	  patients	  will	  have	  reduced	  TPMT	  activity)	  or	  heterozygous	   (some	  will	  have	  a	  
normal	  TPMT	  activity)	  individuals.50	  	  
	  
Multidrug	  resistance	  1	  (MDR1)	  gene	  
It	  has	  been	  shown	  that	  polymorphisms	  in	  MDR1	  gene	  control,	  in	  part,	  the	  expression	  and	  efflux	  
efficiency	  of	  Pgp,	  fact	  that	  have	  been	  described	  in	  several	  studies	  based	  on	  the	  initial	  observation	  
that	   homozygous	   carriers	   of	   the	   T	   allele	   for	   the	   MDR1	   3435	   polymorphism	   present	   a	   lower	  
intestinal	   Pgp	   expression	   and	   therefore	   drug	   absorption	   from	   the	   gastrointestinal	   (GI)	   tract	  
should	   be	   higher	   and	   result	   in	   increased	   plasma	   levels	   .32,55	   Concerning	   MDR1	   G2677T/A	  
polymorphism	   it	   has	   been	   reported	   an	   enhanced	   Pgp-­‐170	   activity	   in	   carriers	   of	   the	   T	   allele	  
(Ser893).56	   In	   a	   study,	   Farrell	  et	   al	  observed	  an	   association	  between	  high	  Pgp-­‐170	  expression	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and	   UC	   patients	   with	   severe	   glucocorticoid-­‐resistant	   disease	   and	   that	   high	   peripheral	   blood	  
lymphocyte	  Pgp-­‐170-­‐expressing	  patients	  are	  more	  likely	  to	  require	  steroids,	  what	  corroborates	  
the	  also	  described	  association	  of	  homozygous	  carriers	  for	  the	  T	  allele	  with	  severe	  UC.56	  	  
Also	   Pgp	   and	  MDR	   expression	  were	   shown	   to	   be	   significantly	   higher	   in	   CD	   and	   UC	   patients	  
requiring	   surgery	   due	   to	   failure	   of	   medical	   therapy,	   fact	   that	   can	   be	   supported	   by	   the	  
observation	   that	   glucocorticoid	   resistance	   was	   found	   to	   be	   associated	   with	   prior	   bowel	  
resection,	   perianal	   disease	   and	   a	   high	   initial	   Crohn’s	   disease	   activity	   index	   (CDAI).54	   The	  
homozygous	  carriers	  of	  the	  T	  allele	  for	  the	  polymorphism	  MDR1	  3435	  C/T	  were	  associated	  with	  
extensive	  UC,	  which	  can	  be	  supported	  by	  an	  reported	  association	  between	  steroid	  refractoriness	  
and	   the	  3435	  TT	  genotype,	  but	   the	  TT	  genotype	   is	   associated	  with	   lower	  expression	  of	  MDR1	  
and	  Pgp170.32	  Other	  study	  by	  Potocnik	  et	  al	  reported	  an	  association	  between	  SNPs	  in	  introns	  13	  
and	  16	  of	   the	  MDR1	  gene	  and	  CS-­‐refractory	   in	  CD	  and	  UC,	  while	  the	  polymorphism	  C3435T	  in	  
exon	  26	  was	  associated	  with	  significant	  or	  complete	  CS	   tapering	  by	  Leuven	  et	  al.50	   It	  was	  also	  
suggested	   that	   these	   MDR1	   polymorphisms	   although	   increasing	   disease	   susceptibility	   for	   CD	  
and	  UC,	  may	  also	  be	  involved	  in	  the	  modulation	  of	  response	  to	  immunossupressors,	  once	  it	  was	  
described	   in	   a	   study	   the	   occurrence	   of	   a	   higher	   frequency	   of	   2677T/3435T	   haplotype	   in	  
azathioprine	  non-­‐responder	  CD	  patients.32	  	  
	  
TNF	  and	  TNF	  receptor	  pathway	  
Novel	   therapeutic	   strategies	   have	   been	   developed	   involving	   the	   TNF	   family	   because	   of	   its	  
participation	  on	  stimulating	   its	  own	  and	  others	  cytokine	  production,	  enhancing	  the	  expression	  
of	  adhesion	  molecules	  and	  neutrophil	  activation	  and	  its	  involvement	  as	  a	  costimulator	  of	  T-­‐cell	  
activation	   and	   antibody	   production	   by	   ß	   cells.52	   The	   interest	   on	   these	   therapy	   relies	   on	   the	  
blockage	   of	   the	   interaction	   between	   TNFA	   and	   the	   accessory	   TNF	   cell-­‐surface	   receptors,	  
important	  in	  the	  pathogenesis	  of	  IBD,	  apoptosis	  cell	  proliferation	  and	  differentiation.52,57	  	  
It	   has	   been	   already	   identified	   different	   SNPs	   in	   the	  TNFA	  promoter	   region	   that	   influence	   its	  
gene	  expression,	  namely	  -­‐238G/A	  that	  is	  associated	  with	  lower	  production	  of	  TNFA	  in	  patients	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with	  UC	  and	  -­‐308G/A	  that	  is	  associated	  with	  enhanced	  TNFA	  production	  in	  cells	  in	  vitro	  and	  in	  
patients	  with	  CD	  in	  vivo.57	  
Despite	   the	  major	   improvement	   in	  quality	  of	   life	  of	   IBD	  patients	  with	   the	  use	  of	  monoclonal	  
antibodies	  to	  TNF,	   it	  should	  be	  noticed	  the	  high	  economical	  costs	  of	  this	  therapy,	  as	  well	  as	   its	  
side	  effects.50	  Nevertheless	  more	  than	  75%	  of	  patients	  are	  responsive,	  but	  resistance	  still	  occurs	  
and	  it	  was	  of	  great	  benefit	   if	  early	  response	  could	  be	  accurately	  predicted	  in	  order	  to	  optimize	  
management	  of	  the	  disease.50	  
When	  comparing	  allele	  and	  genotype	  frequencies	  regarding	  response	  to	  IFX	  or	  ADA	  treatment	  
it	  was	  not	  significant	  in	  the	  TNFA	  -­‐238G/A	  promoter	  SNP	  study,	  but	  it	  was	  reported	  in	  a	  TNFA	  -­‐
308G/A	  promoter	  SNP	  study	  that	  a	  higher	   frequency	  of	   the	   -­‐308A	  allele	  and	  -­‐308GA	  genotype	  
occurs	  in	  no	  responders	  to	  anti-­‐TNF	  treatment	  opposing	  to	  responders	  patients	  (P<0.05).57	  
Other	  known	  aspect	  of	  infliximab	  is	  its	  ability	  to	  induce	  apoptosis	  of	  activated	  T	  lymphocytes,	  
fact	   that	  was	  studied	  by	  Hlavaty	  et	  al	   in	  a	  population	  of	   luminal	  or	   fistulizing	  CD	  patients	  and	  
that	   led	  him	  to	   the	  observation	   that	   in	   luminal	  CD,	  heterozygous	   individuals	   for	   the	  FasL	   -­‐843	  
C/T	  polymorphism	  presented	  a	  74.7%	  versus	  38.1%	  response	  rate	   in	  homozygous	  carriers	  for	  
the	  T	  allele	  (P	  <	  0.01,	  OR	  =	  0.11,	  95%	  CI	  0.08-­‐0.56),	  what	  can	  be	  overthrown	  by	  concomitant	  use	  
of	  AZA.6,50	  For	  the	  homozygous	  carriers	  of	  the	  T	  allele	  for	  the	  CASP9	  93	  C/T	  SNP	  it	  was	  reported	  
a	  positive	  response	  to	  IFX	  in	  opposition	  to	  the	  remaining	  66.7%	  of	  patients	  with	  the	  CC	  and	  CT	  
genotypes	  (P	  =	  0.04,	  OR	  =	  1.50,	  95%	  CI	  1.34-­‐1.68).6,50	  
	  
	  
THERAPY	  IN	  CLINICAL	  CASES:	  A	  PERSPECTIVE	  FROM	  A	  PORTUGUESE	  POPULATION	  
In	   the	   past	   years	   our	   group	   worked	   with	   the	   purpose	   of	   identifying	   clinical	   and	   genetic	  
predictors	   of	   response	   to	   therapy	   in	   IBD,	   which	   may	   become	   of	   potential	   utility	   in	   clinical	  
practice.	  In	  2013	  and	  2014	  we	  published	  the	  results	  driven	  from	  these	  multicenter	  studies	  with	  
participating	   Hospitals	   from	   Central	   Portugal,	   were	   we	   analyzed	   clinical	   parameters	  
characteristic	   from	   both	   diseases	   and	   polymorphisms	   in	   MDR1,	   inflammation,	   apoptosis	   and	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autophagy	   genes.	   In	   both	   studies	   informed	   and	   approved	   by	   the	   Scientific	   and	   Ethical	  
committees	  consent	  was	  obtained	  from	  all	  patients	  entering	  the	  study.	  
Here	   we	   intend	   to	   emphasize	   the	   main	   clinical	   and	   genetic	   predictors	   obtained	   from	   both	  
studies.	  
	  
Application	  of	  therapy	  in	  a	  Crohn’s	  disease	  population	  in	  Portugal58	  
A	   total	   of	   242	   CD	   patients	  were	   eligible	   to	   enter	   the	   study;	  mean	   follow-­‐up	   period	  was	   2.5	  
years.	   In	   terms	  of	  percentage	  of	   responders	   from	  total	  patients	   to	  different	   therapies	  we	  have	  
12%	  responders	  to	  5’-­‐ASA,	  44%	  responders	  to	  corticosteroids,	  41%	  responders	  to	  azathioprine	  
and	  33%	  responders	  to	  infliximab	  (Fig.1).	  
Our	   results	   showed	   that	   in	   terms	   of	   clinical	   parameters	   age	   and	   previous	   surgery	   were	  
identified	   as	   predictors.	   We	   found	   a	   better	   response	   to	   5-­‐ASA	   and	   to	   azathioprine	   in	   older	  
patients	   while	   younger	   ones	   responded	   better	   to	   biologicals	   and	   that	   previous	   surgery	  
negatively	  influenced	  response	  to	  5-­‐ASA	  compounds,	  but	  favoured	  response	  to	  azathioprine.58	  In	  
respect	   to	   genetic	   predictors,	  we	   identified	   a	   relation	  between	   autophagy	  ATGL16L1	  SNP	  and	  
better	  response	  to	  corticosteroids	  and	  CASP9	  C93T	  SNP	  presented	  a	  lower	  chance	  of	  responding	  
both	   to	   corticosteroids	   and	   to	   azathioprine.	  MDR1	   C3435T	   SNP	   related	   to	   a	   higher	   chance	   of	  
responding	   to	   azathioprine,	   while	   MDR1	   G2677T/A	   SNP	   presented	   a	   better	   response	   to	  
azathioprine,	  but	  a	  lower	  chance	  of	  responding	  to	  biologicals.58	  
In	  terms	  of	  response	  to	  the	  switching	  of	  the	  therapy	  when	  it	  became	  necessary	  and	  in	  regard	  to	  
corticosteroids	  we	  observed	  that	  previous	  therapy	  with	  biologicals	  was	  a	  negative	  predictor	  of	  
response	  to	  both	  corticosteroids	  and	  to	  azathioprine.58	  
	  
Application	  of	  therapy	  in	  a	  Ulcerative	  Colitis	  disease	  population	  in	  Portugal59	  
A	   total	   of	   174	   patients	   entered	   the	   study;	   the	   median	   follow-­‐up	   was	   3.9	   years.	   In	   terms	   of	  
percentage	  of	  responders	  from	  total	  patients	  to	  different	  therapies	  we	  have	  64%	  responders	  to	  
5’-­‐ASA,	   30%	   responders	   to	   corticosteroids,	   16%	   responders	   to	   azathioprine	   and	   10%	  
responders	  to	  infliximab	  (Fig.2).	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Several	   clinical	   predictors	  were	   identified,	   namely	   age,	   age	   at	   diagnosis,	   duration	   of	   disease,	  
disease	  extension	  and	  EIM.	  We	  observed	  that	  older	  patients	  and	  those	  diagnosed	  after	   the	  age	  
40	   responded	   positively	   to	   5-­‐ASA	   compounds	   and	   patients	  with	   duration	   of	   disease	   for	  more	  
than	  5	   years	   presented	   a	   negative	   predictor	   of	   response	   both	   for	   5-­‐ASA	   and	   for	   azathioprine,	  
although	   the	   latter	   did	   not	   reach	   statistical	   significance.	   Disease	   extent	   negatively	   influenced	  
response	   to	   5-­‐ASA	   and	   azathioprine,	  with	   patients	  with	   pancolitis	   showing	   poorer	   responses.	  
With	   respect	   to	   EIM,	   we	   observed	   that	   it	   was	   a	   negative	   predictor	   of	   response	   to	   5-­‐ASA,	  
corticosteroids,	   and	   azathioprine	   but	   it	   seemed	   to	   positively	   influence	   response	   to	   biologics,	  
although	  not	  significantly.59	  In	  terms	  of	  genetic	  predictors	  we	  found	  that	  IL23R	  C2370A	  and	  G9T	  
SNPs	  are	  associated	  both	  with	  EIM,	  while	  IL23R	  C2370A	  SNP	  is	  associated	  with	  nonresponse	  to	  
5-­‐ASA	  and	  corticosteroids	  and	  IL23R	  G9T	  SNP	  is	  more	  likely	  to	  respond	  to	  azathioprine.59	  
Previous	  therapies	  also	  seemed	  to	  influence	  response	  to	  several	  drugs,	  since	  previous	  users	  of	  
corticosteroids,	   azathioprine,	   and/or	   biologics	   responded	   better	   to	   5-­‐ASA,	   which	   was	   also	  
observed	  for	  corticosteroids	  and	  azathioprine.59	  
These	  observations	  need	  to	  be	  confirmed	  in	  future	  studies.	  
	  
	  
PERSONALIZED	  MEDICINE:	  IS	  THE	  FUTURE	  ON	  GENETICS?	  
Instead	   of	   searching	   for	   unique	   treatment	   that	   can	   be	   applied	   to	   all	   patients,	   individualize	  
therapy	  seems	  to	  be	  the	  solution	  for	  the	  future.60	  To	  date	  clinical	  characteristics	  of	  disease	  as	  age	  
stratification,	   disease	   location	   and	   extension,	   serologic	   parameters,	   site	   of	   inflammation,	  
severity	  and	  course	  of	  disease	  all	  have	  potential	  to	  predict	  disease	  progression	  and	  complication,	  
and	  thus	  contribute	  to	  the	  physician’s	  individualized	  plan	  of	  treatment,	  but	  it	  is	  now	  recognized	  
the	  importance	  and	  influence	  of	  individual	  patient’s	  genetic	  background.15,27,33	  
In	   the	   recent	   years	  has	   emerged	   the	   concept	  of	  pharmacogenetics,	   described	  as	   the	   study	  of	  
association	   between	   variability	   in	   drug	   response	   and	   genetic	   variation,	   with	   the	   purpose	   of	  
discriminating	   the	   appropriate	   therapy	   regarding	   a	   patient’s	   specific	   genetic	   background	   and	  
promote	  efficacy	  and	  drug	  safety	  rates.50,51	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The	  major	  objective	  of	  the	  pharmacogenetic	  studies	  has	  been	  the	  establishment	  of	  associations	  
between	   genetic	   variation	   and	   response	   and	   side	   effects	   of	   known	   IBD	   therapies,	   once	   its	  
common	  knowledge	  that	  differences	  in	  drug	  response	  are	  related	  to	   functional	  differences	  in	  a	  
gene	  product	  encoded	  by	  different	  alleles	  of	  the	  same	  gene.51	  
But	  genetics	  can’t	  explain	  everything,	   including	   the	   fact	   that	  20%	  to	  30%	  of	   IBD	  patients	  are	  
refractory	  to	  any	  therapy	  despite	  optimal	  dose	  and	  duration,	  side	  effects	  and	  drugs	  toxicity	  are	  
variable	   and	  disease	   duration,	   severity,	   behavior	   and	   concomitant	   therapies	  may	   all	   influence	  
the	  response	  to	  a	  drug.40,50	  Other	  evidence	  is	  that	  heterogeneity	  in	  drug	  effects	  is	  due	  to	  genetic	  
polymorphisms	   in	   drug	  metabolizing	   enzymes	   that	   affect	   active	   drug	   concentrations	   together	  
with	  drug	  receptor	  genetic	  variants.50	  
Quality	   of	   life	   (QoL)	   of	   IBD	   patients	   is	   a	  major	   concern	   for	   the	   physicians	   and	   therefore	   its	  
important	  to	  considerate	  the	  patient’s	  response	  to	  a	  drug,	  both	  the	  therapeutic	  and	  side	  effects.14	  
This	  achievement	  is	  possible	  if	  in	  the	  future	  would	  be	  consider	  the	  analysis	  whether	  earlier	  and	  
more	   effective	   treatment	   of	   CD	   would	   influence	   disease	   activity	   and	   long-­‐term	   outcomes	   for	  
patients.44	  
With	  appropriate	  therapies	  and	  treatment	  regimens,	  deep	  remission	  is	  currently	  achievable	  in	  
a	   minority	   of	   patients,	   and	   because	   of	   that,	   the	   future	   of	   IBD	   treatment	   is	   to	   ensure	   that	   all	  
patients	  achieve	  this	  goal.61	  
Although	  much	  progress	  has	  been	  attained,	   it	   is	  expectable	   that	   in	   the	  near	   future	  aspects	  as	  
new	   therapies	   with	   considerable	   benefits,	   less	   side	   effects	   and	   fewer	   costs	   will	   be	   obtained	  
through	  patients	  genetic	  background	  studies	  in	  order	  to	  predict	  their	  response	  to	  a	  given	  drug.60	  
	  
	  
CHALLENGES	  FOR	  THE	  FUTURE	  
The	   potential	   clinical	   relevance	   of	   identification	   and	   utilization	   of	   clinical	   and	   genetic	  
predictors	   of	   response	   to	   several	   therapies	   available	   to	   treat	   IBD	   is	   to	   gather	   valuable	  
information	   for	   physicians	   in	   order	   to	   help	   them	   assess	   the	   initial	   response	   to	   the	   different	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therapies	  and	  allow	  the	  success	  of	  personalized	  therapy	  and	  the	  achievement	  of	  better	  quality	  of	  
life	  for	  the	  patients.	  
Given	   the	   importance	   of	   mucosal	   healing	   it	   will	   most	   certainly	   be	   of	   great	   importance	   a	  
patient's	  mucosal	  gene	  signature	  in	  order	  to	  achieve	  personalized	  medicine	  once	  it	  will	  allow	  the	  
identification	  of	  therapy	  for	  each	  individual.62	  
It	   is	   expected	   that	   biological	   therapies	   for	   IBD	  will	   be	   developed	   and	  more	   selectively	   used,	  
accordingly	   to	   the	   application	   of	   personalized	   benefit/risk	   analysis	   for	   each	   drug	   through	   the	  
use	  of	  reliable	  biomarkers	  and	  tissue	  signatures.45	  
New	   biologic	   treatments	   are	   currently	   in	   development	   for	   IBD	   and	   they	   mostly	   target	  
leukocyte	  trafficking	  and	  proinflammatory	  cytokines,	  such	  as	  IL6,	  IL17,	  IL18,	  and	  IL21.45	  
It	   was	   recently	   reported	   other	   means	   of	   blocking	   TNF	   like	   anti-­‐TNF	   vaccination,	   TNF	   gene	  
silencing	  with	  small	  interfering	  RNA	  and	  TNF-­‐neutralizing	  nanobodies.62	  	  
Moreover,	   a	   variety	   of	   small	  molecules	   that	   selectively	   inhibit	   signaling	  molecules,	   including	  
protein	  kinase	  C	  and	  NFkß	  are	  currently	  under	  further	  development.	  Finally,	  approaches	  such	  as	  
appendectomy,	   stem-­‐cell	   therapies	   and	   fecal	   transplantation	   are	   also	   being	   assessed	   in	  
controlled	  trials,	  aiming	  to	  target	  the	  pathophysiological	  basis	  of	  IBD.45	  
Regarding	  MDR1	  gene	  it	  is	  enhanced	  the	  importance	  of	  diagnostic	  tests	  for	  the	  discrimination	  
of	  MDR1	  alleles	  with	  the	  goal	  of	  CD	  therapy	  improvement.45	  
Over	   the	   next	   decade	   are	   expected	   advances	   in	   drug	   action	   knowledge,	   appearance	   of	   new	  
drugs	  targets	  and	  a	  greater	  understanding	  of	  the	  genetic	  factors	  that	  determine	  drug	  response.	  
In	  summary,	  it	  is	  desirable	  the	  use	  of	  pharmacogenetic	  as	  a	  daily	  clinical	  practice	  in	  association	  
with	   the	   commonly	   use	   methods	   for	   choosing	   drugs	   and	   selecting	   dosing	   regimens	   applied	  
nowadays.	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CHAPTER IV – DISCUSSION 
 
Crohn’s disease is a heterogeneous disease that presents several differences regarding disease 
severity, location, behaviour and extraintestinal manifestations that may influence therapeutic outcome 
(Pierik et al. 2006). 
It is mostly a disease from the western industrialized countries, which enhances the importance of 
one or more environmental factors involved in its pathogenesis, with higher attention paid to diet, and 
the influence of genetic factors. 
For the disease control with appropriate therapy it is important to identify clinical or genetic predictors 
for a more aggressive phenotype and try to target it. So far, clinical predictors have been the most 
studied ones, allowing the identification of age at diagnosis, disease location and smoking as the most 
significant parameters (Louis et al. 2010). Moreover, other predictors such as serologic markers and 
genetic tests are available, but none of them is predictive enough to be use alone (Yarur et al. 2011). 
More studies are recommended to assess clinical and genetic predictors to improve treatment 
decisions and patients outcomes (Parkes et al. 2014) (Nunes et al. 2013). 
 
With the aim of embracing as many as possible all of the questions regarding the complexity 
involving Crohn’s disease, we have been developing a working project for the past years. Those 
projects intended to clarify some of the known results applied to the Crohn’s disease and Ulcerative 
colitis Portuguese populations. In our work, we have approached several themes involving different 
important components of the disease, namely cytokines associated with the inflammatory pathway, 
biologic processes such as apoptosis and autophagy, clinical and genetic predictors, nutrition and 
response to therapy. Our goal was to comprehend more the IBD development and management in 
order to contribute with some guidelines that could provide a higher quality of life for the patients. 
 
 
 
IV.1 ASSOCIATIONS OF CLINICAL AND GENETIC PARAMETERS  
 
Several studies have demonstrated that clinical factors such as age at diagnosis, disease extent, 
disease location and behaviour at diagnosis are predictive for the development of a more aggressive 
disease and could be used by physicians to delineate therapeutic strategies (Louis et al. 2009). While 
some clinical features show significant associations with adverse prognosis, they are usually 
described retrospectively and many features lack standardization, which leads to a heterogeneity that 
difficult the use of clinical data as predictors for therapy treatment in CD patients (Tamboli et al. 2011). 
Initially, we started to look for clinical and genetic associations with Crohn’s disease that were related 
to the inflammatory pathway, such as pro or antiinflammatory cytokines, and its contribution to the risk 
of developing CD or modifying disease activity. For that, we analyzed 7 polymorphisms in 5 cytokines 
genes (IL1β, IL1RN, TNFα, LTα e IL6) by Polimerase chain reaction (PCR) and PCR/ Restriction 
fragment length polymorphism (RFLP) in a population of 78 individuals with Crohn’s disease and 102 
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control individuals (Ferreira 2006). As significant results in this work, we refer among the genetic 
factors the TNFα -857C/T e IL6 -174G/C polymorphisms as risk factors in disease’s development, with 
a four times higher risk for TT genotype individuals [OR (95%CI) 4.14 (0.81-21.24)] and a ten times 
greater risk for CC genotype individuals [OR (95%CI) 10.39 (2.22-48.77)], respectively, and the TNFα 
-308G/A polymorphism as a protective factor in disease’s development, with a three times greater 
protection for AA genotype individuals [OR (95%CI) 0.31 (0.01-6.97)]. Among the identification of 
associations between polymorphisms and disease’s aggressiveness, we can refer TNFα -857C/T 
polymorphism as a risk factor to a high disease’s activity, with a three times greater risk for the TT 
genotype individuals [OR (95%CI) 2.68 (0.41-17.51)] and IL1β +3953C/T and LTα +252A/G 
polymorphisms as protective factors associated with a less aggressive disease, with a four times 
greater protection for TT genotype individuals [OR (95%CI) 0.23 (0.01-4.71)] and a six times greater 
protection for GG genotype individuals [OR (95%CI) 0.16 (0.01-3.10)], respectively.  
Regarding Crohn’s disease pathogenesis very little is known other than the perpetuation of the 
inflammation it’s probably due to the imbalance between pro and antiinflammatory cytokines as well as 
the resistance of the inflammatory cells to apoptotic stimuli (Louis et al. 1996) (Souza et al. 2005). 
With this in mind we tried to disclose the associations with apoptosis, once it’s established that 
resistance to apoptosis is one major defect in a multifactorial disease such as Crohn’s disease. For 
that, we analysed by PCR/RFLP the Casp9 +93C/T, FasL -843C/T and peroxisome proliferator-
activated receptor gamma (PPARγ) +161C/T and Pro12Ala SNP in a population of 99 individuals with 
Crohn’s disease and 116 control individuals. As results, we have seen that none of the polymorphisms 
analyzed influenced disease susceptibility and/or activity, as can be seen in the paper 1 in chapter II. 
Another important theme to uncover related to CD management is the phenotype-genotype relations 
in association with response to therapy. Although determination of clinical phenotype remains 
complex, ongoing efforts are being made to standardize a clinical classification scheme for IBD 
(Tamboli et al. 2011). Its usefulness to physicians is the identification of clinical and genetic predictors 
that allows them to apply the appropriate therapy for each specific individual based on its clinical and 
genetic profile background. Several studies have been developed along the years with major focus in 
genetic polymorphisms involved in drug transporters, proinflammatory cytokines, apoptosis and 
autophagy, among others important pathways. 
In order to contribute to this purpose, we developed a multicenter study, as can be seen in paper 2 in 
chapter III, were we have analyzed several SNPs in MDR1, IL23R, Casp9, Fas, FasL and ATG16L1 
genes by real-time PCR in 242 CD patients from several participating hospitals from Central Portugal. 
As results, we have seen that polymorphic allele carriers for IL23R G9T and C2370A SNPs had less 
frequently upper GI involvement as compared to wild-type carriers [OR (95%CI) 0.4 (0.02-0.82), 
p=0.008] and [OR (95%CI) 0.25 (0.06-0.86), p=0.03], respectively. Also, individuals with the TT 
genotype for the FasL C844T SNP exhibited more often an inflammatory behaviour (B1) [OR (95%CI) 
0.38 (0.18-0.82), p=0.014]. No other significant associations were observed for the remaining 
polymorphisms and disease characteristics, what was expected at least for the MDR1 G2677T/A 
polymorphism once it has been already described (Ardizzone et al. 2007). 
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Afterward a similar project was designed for the identification of clinical and genetic predictors and its 
association with response to therapy in Ulcerative colitis patients, for us to have a large perspective 
that embraces the totality of inflammatory bowel diseases. Therefore, we developed a multicenter 
study, as can be seen in paper 3 in chapter III, were we have analyzed four SNPs in IL23R gene, 
namely G1142A, C2370A, G43045A and G9T, by real-time PCR in 174 CD patients from several 
participating hospitals from Central Portugal. As results, we observed that carriers of IL23R C2370A 
and IL23R G4305A alleles were at increased risk of presenting extraintestinal manifestations. No other 
significant association was observed between another phenotypic characteristics and genetic 
polymorphisms in IL23R gene. 
 
 
 
IV.2 NUTRITION EFFECTS ON CROHN’S DISEASE PATIENTS 
 
Nutritional support is a vital component of the management of patients with CD. 
Through time and with the evolution in modern science and knowledge, emerges in the 21s century 
the study of how nutrition and genetic could relate and how these association influence CD disease 
course in order to obtain guidelines that would be given by physicians to patients to live a more 
healthy and long life and avoid multiples therapies and illness.   
Nowadays, we know that dietary patterns could influence disease risk by modifying specific 
pathways involved in disease course or activity, nutrients are able to influence direct or indirectly gene 
expression and the effects of diet on disease depend on individual genetic susceptibility profile. 
Based on these assumptions, nutrigenetics tends to identify and characterized the different human 
genetic variations responsible for nutrients metabolism alteration, leading to the understanding of how 
individual genetic profile influence response to diet.  
The main goal to be achieved is the personalization of diet to each CD patient based on the 
individual genetic identity trough the use of specific nutritional guidelines, which will lead to the use of 
nutritional therapy.  
Although it’s an emerging field, further studies are needed to allow nutritional therapy to be use as 
current clinical practice in CD. 
With this in mind our group developed two studies to approach this thematic and verifiy if any 
significant results would be obtained.  
In our earliest study (Guerreiro et al. 2009), we approached the nutritional question in a population 
of 78 individuals with Crohn’s disease and 102 control individuals, where we applied a 
Semiquantitative Food Frequency Questionnaire (FFQ). In what concern the nutrition factors in 
association with polymorphisms and disease’s aggressiveness, we can refer glicids, lipids, saturated, 
monounsaturated and polyunsaturated fats as risk factors to increase the disease’s aggressiveness 
when consumed in higher quantities for the majority of the polymorphisms studied, except for TNFα -
308G/A, LTα +252A/G and TNFα -857C/T polymorphisms, where we couldn’t established any 
significant association between disease’s aggressiveness and genetic and nutrition factors. The 
association between fat, particularly saturated fat and inflammation, has been previously reported 
CHAPTER	  IV.	  DISCUSSION	  
	  
	   78	  
once it increases monocyte production of TNFα, IL1β and IL6 among other proinflammatory cytokines 
(Mozaffarian et al. 2004). Contrarily, high intakes of ω-3 fatty acids were shown to diminish circulating 
levels of proinflammatory cytokines (Tucker 2007). We also observed that the detrimental effect of a 
greater intake of saturated or monounsaturated fat was higher in individuals with the variant allele for 
the TNFα -857C/T and IL6 -174G/C polymorphisms, with the first polymorphism also being referred as 
a promoter factor in the presence of a diet poor in ω-3 fatty acids. In summary, with this study, we 
gained knowledge that the IL6 -174G/C polymorphism was the genetic factor with more associations 
with disease’s aggressiveness and nutrition factors and that differences in the type of dietary fat may 
be important in modulating intestinal inflammation, since we have seen that a diet rich in 
monounsaturated fat seems to be associated with a more active disease and ω-3 polyunsaturated 
fatty acids may have a protective role in CD in opposition to ω-6 polyunsaturated fatty acids. 
Another topic of interest is the previous described basic pathogenic defect of resistance to apoptosis, 
namely of T-cells, that characterizes CD and leads to a perpetuated inflammation in the intestinal 
mucosa. Previously, polymorphisms in apoptotic genes have been associated with heterogeneous 
phenotypes and different responses to CD therapies (Hlavaty et al. 2005). With these assumptions, 
we explored the associations between the Casp9 +93C/T, FasL -843C/T and PPARγ +161C/T and 
Pro12Ala SNP and dietary fat intake in a population of 99 individuals with Crohn’s disease and 116 
control individuals, since previous studies have shown that dietary fat has the ability of affecting 
cellular kinetics by interfering with important processes such as apoptosis induction, cell proliferation 
and cell differentiation (Llor et al. 2003).  
In our study, here described in the paper 1 in chapter II, we verified that a high intake of total, 
saturated and monounsaturated fats and a higher ratio of ω-6/ω-3 polyunsaturated fatty acids were 
associated with a more active phenotype (p<0.05), which is in accordance with the fact that the 
combination of both ω-6 and ω-3 polyunsaturated fatty acids are associated with lowest levels of 
inflammation as suggested before (Pischon et al. 2003). We observed a more detrimental effect of a 
high intake of total and trans fat in wild type carriers of the Casp9 +93C/T polymorphism [OR (95% CI) 
4.64 (1.27-16.89), p=0.020] and [OR (95% CI) 4.84 (1.34-17.50), p=0.016], which led us to 
hypothesize that wild type carriers might exhibit more resistance to apoptosis and therefore, there 
would be a synergism between two potentially harmful factors. However, this may not be as clear as 
that since we have observed that high intake of saturated and monounsaturated fat is already 
associated to a more active phenotype by itself and because it presents comparable effects on wild 
type and polymorphic allele carriers. For PPARγ Pro12Ala SNP, we also observed that a high intake of 
saturated and monounsaturated fat was associated to a more active disease in wild type carriers [OR 
(95% CI) 4.21 (1.33-13.26), p=0.014] and [OR (95% CI) 4.37 (1.52-12.51), p=0.006], what is in 
conformity with previous studies (Debril et al. 2001) (Gong et al. 2005). Those studies shown that the 
Pro→Ala change may cause a conformational change in the protein and consequently patients wild 
type carriers of this polymorphism would have less inhibition of NFκβ pathway, which is known to be 
part of a central signalling pathway that stimulates the transcription of multiple genes that encode 
proinflammatory molecules, and therefore would exhibit a more aggressive and active phenotype. 
Finally, a high intake of ω-6 polyunsaturated fatty acids was associated with a more active disease in 
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wild type carriers for the FasL -843C/T polymorphism [OR (95% CI) 5.15 (1.07-24.74), p=0.041], which 
it’s not in congruity with previous studies. It is known that the carriers of the C allele for this 
polymorphism have a threefold increased binding capacity to the CAAT enhancer protein and 
subsequently a threefold higher expression of FasL that leads to an increase of apoptosis of the active 
cells which are expressing Fas and consequently, wild type carries would be more susceptible to 
apoptosis and, theoretically, exhibit a less severe phenotype (Hlavaty et al. 2005) (Wu et al. 2003). 
These opposite results may be explained, first of all by recalling that interactions between nutrients 
and genes may be extremely complex, but also reminding the existence of two main pathways of 
apoptosis, the extrinsic pathway which is between others Fas dependent and the intrinsic pathway, 
and therefore we may hypothesize that ω-6 polyunsaturated fatty acids influence apoptosis by 
interfering in the intrinsic pathway, among others hypotheses. 
To our knowledge these were the first studies that examining the interactions between 
polymorphisms of proinflammatory cytokine genes and apoptosis genes and the type of fat intake in 
modulating disease activity in patients with Crohn’s disease. 
It has been observed that the interaction of dietary components with the host’s mucosa and 
alteration of resident intestinal gut microbiome provides new insights into its mechanism of action in 
IBD pathogenesis. Changes in dietary intake of food components (e.g., fatty acids, carbohydrates, 
proteins and peptides, prebiotics, and probiotics) modulate gene expression in host intestine, as well 
as in liver, adipose tissue, and muscle and change the intestinal gut microbiome composition 
(Fergunson 2013). 
The introduction of the concept of nutrigenetics as a routine tool to assess the management of CD is 
not a reality, but has taken in consideration the known pathways suggested to be involved and used 
them for specific dietary guidelines based in the previously described genes. The main goal is to 
achieve personalized nutrition to guarantee disease prevention and treatment.  
 
 
 
IV.3 PHENOTYPE-GENOTYPE RELATIONS IN ASSOCIATION WITH RESPONSE TO 
THERAPY 
 
Crohn’s disease and ulcerative colitis are chronic disabling inflammatory bowel diseases. The 
treatment of IBD has focused on the management of symptoms but is becoming more resolute on 
changing the course of the disease and its complications in the long-term (Magro et al. 2012). 
The main goals in treating Crohn’s disease involve healing the intestinal mucosa, prevent CD 
complications, hospitalization and surgery, induce and maintain remission, improve patient’s quality of 
life and minimize applied therapeutic toxicity (Panaccione et al. 2012). 
In a heterogenic disease like CD, treatment response may vary depending on several factors such 
as duration of disease, disease behaviour and severity as well as those related with individual genetic 
background and polymorphisms in particularly drug metabolizing enzymes or target proteins (Pierik et 
al. 2006). 
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Pharmacogenetics appears as the study of the existing associations between variability in drug 
response and/or drug toxicity and genetic polymorphisms, aiming to a more efficacious and safe 
applicability of appropriate therapeutic to each CD patient based on his specific genetic profile (Pierik 
et al. 2006). 
During our project work, it has come to our attention the growing interest in finding clinical and/or 
genetic predictors for the susceptibility or development of CD, in order to apply appropriate therapeutic 
to individual patients. Consequently, we have designed two different retrospective studies to identify 
clinical or genetic predictors for IBD and their association with response to therapy. 
We have introduced this thematic with a multicenter study, as can be seen in paper 2 in chapter III, 
were we have analyzed several SNPs in MDR1, IL23R, Casp9, Fas, FasL and ATG16L1 genes by 
real-time PCR in 242 CD patients from several participating hospitals from Central Portugal, in order to 
identify the associations between clinical characteristics, polymorphisms and response to the 
commonly used therapy in CD management, namely 5’ASA, corticosteroids, azathioprine and 
biological therapies. For clinical predictors we have identified that older patients responded better to 
5’ASA and to AZA [OR (95%CI) 1.07 (1.02-1.14), p=0.003] and [OR (95%CI) 1.03 (1.01-1.06), 
p=0.01], respectively, while younger ones responded better to biologics [OR (95%CI) 0.95 (0.90-1.00), 
p=0.06], previous surgery negatively influenced response to 5’ASA [OR (95%CI) 0.25 (0.05-0.96), 
p=0.05], but favoured response to AZA [OR (95%CI) 2.1 (1.04-4.49), p=0.04] and, finally we observed 
that patients with perianal involvement had a worse response to corticosteroids [OR (95%CI) 0.32 
(0.14-0.72), p=0.006]. Regarding genetic predictors we observed that homozygotes TT for Casp9 
C93T SNP had a lower change of responding both to corticosteroids [OR (95%CI) 0.23 (0.36-0.88), 
p=0.03] and azathioprine [OR (95%CI) 0.08 (0.01-0.51), p=0.02] and individuals TT genotype for the 
MDR1 C3435T SNP had a higher chance of responding to azathioprine [OR (95%CI) 2.38 (1.13-5.02), 
p=0.01]. Carriers for the polymorphic allele of MDR1 G2677T/A SNP responded better to AZA [OR 
(95%CI) 1.89 (0.94-3.81), p=0.07], but have a lower chance of responding to biologics [OR (95%CI) 
0.31 (0.08-1.07), p=0.07], which became significant after adjusting for gender [OR (95%CI) 0.75 (0.24-
0.63), p=0.05]. The results obtained for the association between MDR1 gene SNPs and response to 
azathioprine are in disagreement with a previous study that investigated the influence of G2677T/A 
and C3435T MDR1 gene polymorphisms on the efficacy of azathioprine in inducing remission in CD 
patients, where it was observed higher frequencies of the 2677TT and 3435TT genotypes and the 
2677T/3435T haplotype in CD patients that did not respond to azathioprine (Mendoza et al. 2007). 
In the present study, we decided to use long-term response (more than 1 year) because we believe 
that this concept is clinically more relevant. We have seen that 12% of the population responded 
better to 5’ASA therapy and, although it’s a low number of patients, emphasizes the importance of 
identifying those patients who respond better just with less aggressive and toxic therapies, since a 
systematic review of clinical trials (Su et al. 2004) have demonstrated that 18% of patients entered 
remission with placebo alone, which may suggest that in our population these patients could be 
treated with 5’ASA compounds alone. The identification of surgery as a negative predictor of response 
to 5’ASA, but a positively one for response to azathioprine, is clinically very important once suggests 
to the physician that after the resection of the diseased segment the patient should start 
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immunosuppression therapy instead of milder therapies as 5’ASA, ending with commonly doubts 
about which treatment to choose after surgery. The results obtained for the genetic predictors 
associated with response to therapy gave us some important guidelines that might be relevant in 
clinical decisions, nevertheless further studies in bigger populations are needed. 
The understanding of Crohn’s disease is nowadays more explored than Ulcerative colitis, since it’s 
more difficult to predict disease course in UC. In routine clinical practice physicians treat UC patients 
with 5’ASA therapies because of its treatment success and therefore the main goal to achieve in 
studies trying to unravel the most appropriate therapies to treat UC would be to identify whose patients 
are 5’ASA nonresponders and should be started on more aggressive and effective therapies as early 
as possible. 
For this reason, a similar project was designed for the identification of clinical and genetic predictors 
and its association with response to 5’ASA, azathioprine, corticosteroids and biologic therapies in 
Ulcerative colitis patients, for us to have a large perspective that embraces the totality of inflammatory 
bowel diseases. Therefore, we developed a multicentre study, as can be seen in paper 3 in chapter III, 
were we have analyzed four SNPs in IL23R gene, namely G1142A, C2370A, G43045A and G9T, by 
real-time PCR in 174 CD patients from several participating hospitals from Central Portugal. As 
results, we have seen that older patients and those diagnosed after the age 40 responded better to 
5’ASA [OR (95%CI) 1.03 (1.00-1.05), p=0.004] and [OR (95%CI) 2.26 (1.21-4.57), p=0.01], 
respectively, in opposition to duration of disease for more than 5 years that was a negative predictor of 
response for both 5’ASA and azathioprine, although the latter did not reach statistical significance [OR 
(95%CI) 0.37 (0.17-0.77), p=0.008] and [OR (95%CI) 0.26 (0.05-1.16), p=0.07], respectively. Patients 
with pancolitis presented poorer responses to 5’ASA and azathioprine [OR (95%CI) 0.15 (0.04-0.49), 
p=0.002] and [OR (95%CI) 0.18 (0.03-0.99), p=0.05], respectively. Previously works have shown that 
young age, female sex and extensive colitis presented less probability of responding to 5’ASA therapy 
(Langholz et al. 1994) (Hoie et al. 2007) (Solberg et al. 2009). In our case, none of these predictors 
were identified. Regarding extraintestinal manifestations, we observed that it was a negative predictor 
of response to 5’ASA, corticosteroids and AZA [OR (95%CI) 0.25 (0.10-0.56), p=0.001], [OR (95%CI) 
0.35 (0.11-1.06), p=0.06] and [OR (95%CI) 0.18 (0.04-0.76), p=0.02], respectively, but it seemed to 
positively influence response to biologics, although not statistically significant [OR (95%CI) 8.00 (0.72-
88.22), p=0.09]. To our knowledge the results from extraintestinal manifestations weren’t clearly 
reported before. All that is published refers that EIM are among the clinical risk factors that may be 
associated with disease extent and severity (Farmer et al. 1993), and a recent review (Veloso 2011) 
suggests that early aggressive therapy may be required for treating several EIMs in order to prevent 
chronic damage. This suggestion is in accordance with our results since it was shown that EIM was a 
negative predictor of response to 5’ASA, corticosteroids and AZA, therefore suggesting the use of 
more aggressive therapeutic like biologic therapy. 
In reference to genetic predictors to UC very less is known compared to CD, once only a few clinical 
settings have investigated it (Beaugerie & Sokol 2012). In our work, we studied the associations of 
IL23R gene polymorphisms with response to therapy, since it’s recognized that IL23 cytokine is 
essential to drive the chronic intestinal inflammation in IBD, particularly in UC (Morrison et al. 2011), 
CHAPTER	  IV.	  DISCUSSION	  
	  
	   82	  
and that IL23R gene variants contributes to colitis pathogenesis through several pathways, thereby 
resulting in different types of responses (Safranny et al. 2013). In what concerns genetic predictors we 
have seen that individuals with the AA genotype for the IL23R C2370A SNP negatively influenced the 
response to 5’ASA and corticosteroids [OR (95%CI) 0.32 (0.11-0.92), p=0.03] and [OR (95%CI) 0.19 
(0.04-0.84), p=0.02], respectively, while individuals with the GG genotype for the IL23R G9T SNP 
were more likely to respond to azathioprine [OR (95%CI) 11.8 (1.00-139.0), p=0.05]. Early indicators 
of need of azathioprine therapy were already described in previous studies (Jurgens et al. 2010). 
 Once again we decided to use long-term response (more than 1 year) because we believe that this 
concept is clinically more relevant. As was expected from previous works, over 60% of our UC 
patients responded positively to 5’ASA compounds while the other 40% that were refractory to 5’ASA 
were started on azathioprine, and from this latter group 58% of them responded well to azathioprine 
while the others ultimately required biologic therapy. Regarding clinical predictors none of the 
previously described were found but new ones rise, such as older patients and those diagnosed after 
the age 40 responded better to 5’ASA, duration of disease for more than 5 years was a negative 
predictor of response for both 5’ASA and azathioprine, although the latter did not reach statistical 
significance. Patients with pancolitis presented poorer responses to 5’ASA and azathioprine and 
finally, extraintestinal manifestations was a negative predictor of response to 5’ASA, corticosteroids 
and AZA, but it seemed to positively influence response to biologics, although not statistically 
significant. For genetic predictors we identified IL23R C2370A SNP as a poorer responder to 5’ASA 
and corticosteroids therapies, while IL23R G9T SNP is most likely associated with a positive response 
to azathioprine, fact that is supported by previous indications that encourage an early use of 
azathioprine therapy. All these findings might be extremely important in clinical practice, nevertheless 
further studies are still needed. 
All of the previous results described have shown us the importance of researching in the different 
existing fields of knowledge that are available for IBD and the ultimate purpose of determining clinical 
and genetic predictors to response to therapy that would guide physicians to the concept of 
personalized medicine. This necessity has led us to write a review article, as can be seen in paper 4 in 
chapter III, where we tried to approach the importance of the genetic factors in the determination of 
susceptibility to IBD, the existing conventional therapies and its advantages/disadvantages, the 
identification of genetic predictors of response to therapy, including a perspective from the studies we 
have developed in a Portuguese population and, finally, the importance of genetic in personalized 
medicine and challenges for the future to come. 
Long before GWA studies, the NOD2 (chromosome 16q12), IBD5 (chromosome 5q31) and HLA 
class II (chromosome 6p21) associations with IBD were the most studied ones, regarding the 
identification of susceptibility genes to CD (Cho & Weaver 2007) (Brant 2013). More recently, we have 
seen emerging important data on the associations with ATG16L1 (chromosome 2q37), IRGM 
(chromosome 5q33) and IL23R (chromosome 1p31) as susceptibility genes to CD (Stappenbeck et al. 
2011). Many other genes have been studied along the years, namely apoptotic genes like Fas, FasL, 
Casp9, inflammatory response related genes like TNFα, LTα, IL1, IL6 and drug response genes like 
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MDR1, but in any manner they don’t appear as risk disease genes (Waterer & Wunderink 2003) (Ho et 
al. 2005). 
Genetic markers are emerging as powerful tools for patients stratification once they are stable over 
time and not suitable for subjective interpretation, but further studies are needed for its use in regular 
basis (Vermeire et al. 2010). Recent advances in this area have led to the concept of 
pharmacogenetics that permits not just the explanation of interindividual variability in drug response, 
but most importantly the prediction of efficacy and adverse drug events in different patients before the 
initiation of the treatment. The major focus on pharmacogenetics research has been on allelic variants 
in drug-metabolizing enzymes (DMEs), but other genetic locus have gain relevance such as MDR1 
gene and the TNF/ TNF receptor pathway (Mascheretti et al. 2004). 
With all the scientific advances in this field, individualize therapy seems to be the solution for the 
future. Nevertheless it’s important to remember that clinical and genetic parameters can’t explain 
everything, including the fact that 20-30% of IBD patients are refractory to any therapy despite optimal 
dose and duration, side effects and drugs toxicity are variable and disease duration, severity, 
behaviour and combined therapies may all influence the response to a therapy (Mascheretti et al. 
2004). The achievement of a better quality of life for CD patients should, accordingly with the 
previously mention, consider the analysis whether earlier and more effective treatment would influence 
disease activity and long-term outcomes for patients. 
This type of studies and the predictors that we identified here will help a better prediction of disease 
outcome and the possibility to stratified patients in subgroups that will allow the correct application of 
the most efficacious therapy for each case, minimizing toxicity and costs. 
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CHAPTER V – FINAL REMARKS AND FUTURE PERSPECTIVES 
 
Crohn’s disease is a chronic relapsing disease with high phenotype heterogeneity and no cure 
available so far. Its precise etiology remains unknown, but is certain the involvement of clinical, 
genetic and environmental factors. 
For the last decades relevant advances have been made in the fields of clinical, genetics, 
immunology, microbiology and therapy in IBD, that have led us to a better understanding of a complex 
disease such as Crohn’s disease. 
In line with these advances, our group have approached distinctive areas of study related with 
Crohn’s disease and more lately to Ulcerative colitis and Inflammatory bowel diseases globally. With 
these purposes we designed a study that included the inflammatory response pathways, biologic 
processes as apoptosis and autophagy, nutrigenetics, therapeutic and pharmacogenetics components 
on a Portuguese population from different participating hospitals. To achieve it we initiated clinical data 
collection, genetic analysis with PCR/RFLP and real-time PCR techniques of relevant gene 
polymorphisms, study of diet patterns and response to therapies data collection. 
All of the aims proposed in this dissertation were achieved through the analysis of data collected, 
study of important phenotype-genotype associations for CD susceptibility and/or development, 
investigation of the effects of dietary patterns in disease activity and search of phenotype-genotype 
relations in association with response to therapy.  
Throughout our work the main purpose was the identification of guidelines that would possibly be 
used by physicians to stratified patients in order to receive personalized therapy accordingly to their 
disease prognosis, looking at it as a contribution to a step forward into individualized CD treatment. 
Several results were obtained along the way, but it’s pertinent to emphasized the importance of: 
- TNFα, LTα, IL1 and IL6 cytokines as associated with disease aggressiveness and 
development; 
- FasL apoptotic gene as related to disease behaviour; 
- IL23R cytokine associated with a greater risk of developing EIM in UC patients; 
- glicids, lipids, saturated, monounsaturated and polyunsaturated fats as risk factors to increase 
the disease’s aggressiveness when consumed in higher quantities for the majority of the 
polymorphisms studied; 
- identification of clinical predictors such as patients age, surgery and perianal involvement and 
genetic predictors like Casp9 and MDR1 gene polymorphisms in association with response to 
therapy for Crohn’s disease; 
- description of clinical predictors such as patients age, age at diagnosis, duration of disease, 
pancolitis and extraintestinal manifestations and genetic predictors like IL23R gene 
polymorphisms in association with response to therapy for Ulcerative colitis; 
 
Our study has revealed some important guidelines, but further studies are still needed for the 
success of personalized therapy and the achievement of a better quality of life for CD patients. For 
these reasons, some new goals for our study could be drawn, namely the verification of the obtained 
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guidelines in a greater population; the identification by testing in cell cultures with commercial cell lines 
of the best therapy, among the studied ones, that should be applied to specific groups of patients 
divided based on their phenotype-genotype associations; the analysis of emerging important gene 
polymorphisms that have been recently related to CD and the study of its association with phenotype 
and response to therapy and, lastly with the importance that autophagy has gained in the regulation of 
immune and/or inflammatory responses, it may be interesting to study the modulation of this signalling 
pathway to restore and control the imbalance inflammatory responses in CD patients. 
Nowadays, several hypotheses have been suggested and are being exploited worldwide, namely the 
use of pretreatment genetic screening based in a combination of genetic tests, serologic markers and 
determined disease characteristics in order to select an optimal dosage and schedule a more 
effective, safer and less expensive therapeutic directed to each patient; mucosal gene signature given 
the importance of mucosal healing in CD; identification of reliable biomarkers and tissue signatures; 
development of new biologic treatments that mostly target leukocyte trafficking and proinflammatory 
cytokines such as IL6, IL17, IL18 and IL21; blockage of TNF with anti-TNF vaccination, TNF gene 
silencing with small interfering RNA and TNF-neutralizing nanobodies; development of a variety of 
small molecules that selectively inhibit signalling molecules; diagnostic tests for the discrimination of 
MDR1 gene alleles and, finally, approaches like stem-cell therapies and fecal transplantation. 
There is currently available several genetic information to improve drug therapy and, therefore, 
significant development is expected to occur throughout the next decades in accordance with the 
emerging of new techniques, medical availability, new knowledge that will allow individual genetic 
background to be studied for prediction of response to therapy. 
The future will rely in the application of pharmacogenetics and nutrigenetics guidelines in daily 
clinical practice for Crohn’s disease management, in order to induce and maintain remission through 
appropriate therapeutic and diet patterns that ultimately will contribute to a better quality of life for CD 
patients. 
 
 
 
	  
	  
 
 
 
 
 
	  
